WO2005063725A1 - フェニルプロパン酸誘導体 - Google Patents
フェニルプロパン酸誘導体 Download PDFInfo
- Publication number
- WO2005063725A1 WO2005063725A1 PCT/JP2004/019749 JP2004019749W WO2005063725A1 WO 2005063725 A1 WO2005063725 A1 WO 2005063725A1 JP 2004019749 W JP2004019749 W JP 2004019749W WO 2005063725 A1 WO2005063725 A1 WO 2005063725A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- phenyl
- methyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel compound having a GPR40 receptor function regulating action and useful as a therapeutic agent for diabetes.
- GPCRs G Protein-coupled Receptors
- P PAR peroxisome proliferator-activated receptor
- CR 1 optionally substituted 5-membered aromatic heterocyclic group
- X bond, 0, S, -NR 6- (R 6 : H, optionally substituted hydrocarbon group, etc.);
- Q ( ⁇ _ 2 divalent hydrocarbon group; Y:.
- alkanoic acid derivative represented by is useful as a preventive-therapeutic agent for diabetes, hyperlipidemia, impaired glucose tolerance and the like. '
- WO 99/11 255 pamphlet has the formula:
- R 1 - 8 alkyl, - 8 alkoxy, halogen atom, triflate Ruo b, such as methyl;
- R 2 -C00R 3 (R 3: H, - 4 alkyl) or the like;
- A - 8 alkylene or the like;
- G: - 8 E 1 ( ⁇ -8 alkylene, etc .;
- E 2 :-0_, etc .;
- E 3 Single bond, etc .;
- n alkyl, alkoxy, halogen atom, trifluoromethyl or carbocyclic ring which may be substituted with -toro; 0, 1; Cy Cl ring: absent etc.
- the compound represented by is useful as a PPAR ligand receptor binding agent, a PPAR receptor agonist, and a PPAR receptor antagonist, and is used as a therapeutic agent for diabetes.
- the pamphlet of International Publication No. 0 I / O 0603 has the formula:
- the compound represented by is used as a P PAR ⁇ agonist, and is disclosed to be useful as a prophylactic and therapeutic agent for P PAR ⁇ -mediated diseases (eg, hyperlipidemia, arteriosclerosis, type 1 or 2 diabetes). Have been.
- P PAR ⁇ -mediated diseases eg, hyperlipidemia, arteriosclerosis, type 1 or 2 diabetes.
- A at least 0, N, a hetero atom selected from S 5 comprises one - heterocycles, etc., to 6-membered;
- B - 6 alkylene, etc.;
- ALK - 3 alkylene;
- R 1 H, Anorekinore;
- Z halogen -(Cw alkylene) phenyl which may be substituted with
- the compound represented by is useful as a PPAR ⁇ agonist and can be used as a preventive / therapeutic agent for hyperglycemia, type 1 or type 2 diabetes, hyperlipidemia and the like.
- the compound represented by is useful as a therapeutic agent for PPAR-related diseases, for example, a therapeutic agent for type 2 diabetes, impaired glucose tolerance, insulin resistance, hypertriglyceridemia, etc. ing.
- An object of the present invention is to provide a novel compound having a GPR40 receptor function regulating action, which is useful as an insulin secretagogue or a prophylactic / therapeutic agent for diabetes and the like.
- the present inventors have conducted various studies and found that the compound represented by the following formula (I) has unexpectedly excellent GPR40 receptor agonist activity, and furthermore has properties such as stability and the like as pharmaceuticals. Have been found to be safe and useful as preventive / therapeutic agents for GPR40 receptor-related conditions or diseases in mammals, and completed the present invention based on these findings. .
- R 1 and R 2 are the same or different, each represents a hydrogen atom, an optionally substituted have good C 6 _ 14 Ariru groups, substituted or may be heterocyclic group or substituted or CI- 6 alkyl group Or R 1 and R 2 combine with each other to form a ring with the carbon atom to which they are attached, E is —W 1 — N (R 5 ) one W 2 —, -W X -CH (R 6 ) — O— W 2 —, —W 1 — O — CH (R 6 ) — —, -W 1- S (O) n- W 2 - or a W 1 - CH (R 6) - not a one (W 1 and W 2 are the same or different, a bond or an optionally substituted have good alkylene group, R 5 and R 6 is an optionally substituted heterocyclic group also have ho optionally substituted hydrocarbon radical, n is 1 or 2. However, when X is S, 1 5 Oyopi 1 6
- the ring S 1 has a benzene ring or a pyridine ring which may further have a substituent selected from an optionally substituted C alkyl group, an optionally substituted Ci-6 alkoxy group and a halogen atom.
- R 3 and R 4 are the same or different and each is a hydrogen atom, a halogen atom,.
- R 9 and R 1 Q are the same or different and each is a hydrogen atom, a halogen atom or C ⁇ - 6 alkoxy group,
- R represents an optionally substituted hydroxy group or an optionally substituted amino group.
- E is —W 1 — N (R 5 ) — W 2 —, -W 1 -CH (R 6 ) —O— W 2 —, — W 1 1 0— CH (R 6 ) —W 2 — Or one Wi—CH (R 6 ) —W 2 — (W 1 and W 2 are the same or different and each represents a bond or an optionally substituted Ci-3 alkylene group, and R 5 and R 6 are substituted also. ⁇ showing a good charcoal hydrocarbon group is heterocyclic group or substituted or, if X is S, sigma 5 Oyobi 1 6 is not. 1 _ 6 Arukiru group.)
- Ring S 1 may be substituted — a 6- alkyl group, an optionally substituted Ci-6 alkoxy group and a benzene ring which may further have a substituent selected from a halogen atom, and
- R 5 is is an optionally substituted C 7 _ 6 Ararukiru group (5).
- a GPR40 receptor function modulator comprising the compound of the above (1), a salt thereof, or a prodrug thereof.
- a medicament comprising the compound of (1) or a salt thereof or a pro'drug thereof.
- a method for preventing or treating diabetes in a mammal comprising administering to the mammal an effective amount of the compound of (1) or a salt thereof or a prodrug thereof. Etc.
- the compound of the present invention, a salt thereof, or a prodrug thereof has an excellent GPR40 receptor function regulating action, and can be used as a preventive or therapeutic agent for diabetes and the like.
- halogen atom in the present specification includes a fluorine atom, a chlorine atom, a bromine atom and an iodine atom unless otherwise specified.
- examples of the “optionally substituted hydrocarbon group” in the present specification include, for example, “optionally substituted alkyl group”, “optionally substituted C 2 — 6 alkenyl group ",” optionally substituted C 2 - alkynyl group ",” optionally substituted C 3 _ 8 cycloalkyl group ",” optionally substituted C
- the “0 ⁇ 6 alkyl group” in the present specification includes, for example, methyl, ethynole, propinole, isopropynole, petinole, isoptinole, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl And hexyl.
- C 2 6 alkenyl group for example Bulle, propenyl, isopropenyl, 2-heptene one 1 one I le, 4-pentenoic one 1 one I le , 5 Kissen 11-yl and the like.
- Examples include 2-putin-1-inole, 4-pentin-1-inole, and 5-hexin-1-inole.
- the "Ji 3 _ 8 cycloalkyl group" in the present specification unless otherwise indicated, eg if cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl can be mentioned up to cycloheteroalkyl. '
- C 6 1 4 Ariru group for example phenyl, 1 one Nafuchinore, 2-naphthyl, 2-Bifueyurinore, 3 Bifueyurinore, 4 Bifue two Lil, 2-anthryl And the like.
- the C 6 - 1 4 Ariru may be partially saturated, 'C 6 partially saturated - The 1 4 Ariru, for example, tetrahydronaphthyl and the like.
- C 7 _ 1 6 Ararukiru group unless otherwise noted, benzyl
- the “optionally substituted hydroxy group” in the present specification includes, for example, a “hydroxy group”, an “optionally substituted. good containing alkoxy group) ", '' substituted optionally heterocyclic Okishi group optionally”, “substituted C 6 _ 1 optionally 4 Ariruokishi group”
- the “. ⁇ 6 alkoxy group” in the present specification includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy and the like.
- examples of “di. Alkoxy group” include heptyloxy, octyloxy, nonyloxy, decyloxy and the like in addition to the above 6 alkoxy groups.
- heterocyclic oxy group in the present specification, a hydroxy group substituted by a “heterocyclic group” described below can be mentioned.
- the heterocyclic oxy group include tetrahydrobilanyloxy, thiazolyloxy, pyridyloxy, bilazolyloxy, oxazolyloxy, cheloxy, and furyloxy.
- C 6 1 4 Ariruokishi group unless otherwise specified, For example, phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like can be mentioned. .
- C 6 aralkyloxy group for example, benzyloxy, phenethyloxy and the like can be mentioned unless otherwise specified.
- 0 ⁇ 6 alkylthio group in the present specification, unless otherwise specified, for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio, hexylthio and the like can be mentioned.
- heterocyclic group in the present specification means, for example, one or two selected from nitrogen, sulfur and oxygen other than carbon as ring-constituting atoms, and 1 to 4 5- to 1.4-membered (monocyclic, bicyclic or tricyclic) heterocyclic group containing one heteroatom, preferably (i) 5- to 14-membered (preferably 5- to 1.0-membered) aromatic And (ii) a 5- to 10-membered non-aromatic heterocyclic group. Among them, a 5- or 6-membered aromatic heterocyclic group is preferable.
- chenyl eg, 2-chenyl, 3-chenyl, etc.
- frills eg, 2 _ frill, 3-furyl, etc.
- pyridyl eg, 2-pyridyl, 3-pyridyl, 41-yl
- thiazolyl eg, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, etc.
- oxazolyl eg, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, etc.
- quinolyl eg, 2— Quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8_quinolyl, etc., isoquinolinol (Example: 1 ⁇ soquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, etc.)
- Pyrazur pyrimidyl (eg, 2-pyrimidyl, 4_pyr
- pyrrolidiel eg, 1-pyrrolidinyl, 2-pyrrolidinyl, 3_pyrrolidyl, etc.
- oxazolidinyl eg, 2-oxazolidinyl, etc.
- imidazolyl eg, 1-imidazolinyl, 2-imidazolyl, 4-imidazolinyl, etc.
- Piperidinyl eg, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, etc.
- piperazinyl eg, 1-pipergel, 2-piperazinyl, etc.
- morpholinyl eg, 2-morpholinyl, 3-morpholinyl, 41-morpholinol, etc.
- thiomorpholinyl eg 2-thiomorpholininole, -'3-thiomonoleforinyl, 4-thiomorpho.riel, etc.
- tetrahydrobiral
- the “.- 6 alkylsulfoyl group” includes, for example, methylsulfoel, ethylsulfonyl, propylsulfonyl, isopropinolesulfol, hexylsulfol and the like.
- alkylsulfinyl group in the present specification includes, for example, methinolesnorefueinole, echinoresnorefininole, propi / resnorefininole, isopropinoreseno Refi-nore, hexinoresnorejuenore and the like.
- C 6 ⁇ 4 arylsulfonyl group examples include, unless otherwise specified, for example, phenylsulfol, 1.1-naphthylsulfonyl, .2-naphthylsulfonyl and the like.
- the “carboxyl group which may be esterified” in the present specification includes, for example, carboxyl, dimethoxy-carboyl (eg, methoxycarbonyl, ethoxycarponyl, propoxycarbonyl, tert-butoxy). carbonyl, etc.), C 6 _ 14 Ariruokishi one carbonyl group (e.g., phenoxy Carbonyl), C 7 —i 6 aralkyloxy monocarbonyl group (eg, benzyloxycarbonyl, phenethyloxycarbol, etc.) and the like.
- alkyl group which may be halogenated in the present specification refers to the above rCi-e alkyl group which may be substituted with 1 to 5 of the above “halogen atoms”.
- halogen atoms for example, methyl, ethyl, propyl isopropyl, butyl, tert-butyl, isobutyl, trifluoromethyl and the like can be mentioned. '
- the “optionally halogenated C 6 alkoxy group” in the present specification refers to the above rc- 6 alkoxy group which may be substituted by 1 to 5 of the above “halogen atoms” ].
- methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethoxy and the like can be mentioned.
- the "mono- or di-C ⁇ 6 Arukiruamino group” in the present specification, unless otherwise cross is, the 6 alkyl group "mono one or di- monosubstituted Amino groups.
- methylamino, ethylamino, propylamino, dimethylamino, ethylmethylamino, getylamino and the like can be mentioned.
- phenylamino, diphenylamino, 1-naphthylamino, 2-naphthylamino, naphthylfuramino and the like can be mentioned.
- “Mono one or di- _C 7 - 16 Ararukiru primary amino group” in the present specification as, unless otherwise stated in particular, the Amino group which is mono- or di-substituted by ".74 6 Ararukiru group” can be mentioned.
- benzylamino, phenethylamino and the like can be mentioned.
- N-C-alkyl one N-C 6 - 14 Ariruamino group in the present specification as a, unless otherwise specified, the "0 ⁇ 6 alkyl group” and the “C 6 _ 14 ⁇ Li Lumpur group And a substituted amino group.
- N-methyl_N-phenylamino, N-ethyl-N-phenylamino and the like can be mentioned.
- N- alkyl one N- C 7 _ 16 7 Rarukiruamino group in the present specification, unless otherwise specified, the "Ji ⁇ alkyl group” ⁇ Pi the "C 7 _ 16 ⁇ Aralkyl group ".
- N-methyl-1-N-benzylamino, N-ethyl-N-benzylamino and the like can be mentioned.
- the term “mono-or di-alkyl- 6- alkyl rubamoyl group” includes, unless otherwise specified, mono- or di-substituted alkyl rubamoyl groups with the above “0 ⁇ 6 alkyl group”.
- methyl carbamoyl, ethyl carbamoyl, isopropyl carbamoyl, hexyl carbamoyl, dimethyl carbamoyl, dimethyl carbamoyl, ethyl carbamoyl and the like can be mentioned.
- the term ⁇ mono- or di-5- to 7-membered heterocyclic monofunctional rubamoyl group '' includes, unless otherwise specified, a mono- or di-substituted mono- or di-substituted functional rubamoyl group.
- the 5- to 7-membered heterocyclic group includes, as a ring-constituting atom, a heteroatom containing one or two or one to four heteroatoms selected from nitrogen, sulfur and oxygen atoms in addition to carbon atoms. And a ring group.
- heterocyclic group examples include chloro, furyl, pyridyl, thiazolyl, oxazolyl, pyrazinyl, pyrimidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridazinyl, isothiazolyl, and isooxazolyl.
- Preferred examples of the “mono- or di-5- to 7-membered heterocyclic monovalent rubamoyl group” include 2-pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-phenylcarbamoyl, and 3-chloro- Rucarbamoyl and the like.
- the “mono- or dialkyl-sulfamoyl group” in the present specification unless otherwise specified, a sulfamoyl group mono- or di-substituted with the above “C i- 6 alkyl group” is used.
- Examples include methylsulfamoyl, ethylsulfamoyl, propylsulfamoyl, isopropylsulfamoyl, hexylsulfamoyl and the like.
- Ci-io alkoxy group includes, for example, (1) a halogen atom; (2) a hydroxy group; (3) an amino group; (4) nitro group; (5) cyano group '; (6) halogen atom, hydroxy group, amino group, nitro group, cyano group, optionally halogenated C- 6 alkyl group, monono or di-C - 6 Arukiruamino group, C 6 - 14 Ariru group, mono- one or di- one C 6 - 14 Ariru primary amino groups, C 3 - 8 cycloalkyl group, Cj - 6 alkoxy group, d-6 alkylthio group, C - 6 alkyl Surufieru group
- Heterocyclic group optionally substituted with 1 to 3 'substituents selected from arylusulfamoyl groups (preferably furyl, pyridyl, chenyl, pyrazolyl, thiazolyl, oxazolyl, 2-oxo-1, 3-dioxole-4);
- arylusulfamoyl groups preferably furyl, pyridyl, chenyl, pyrazolyl, thiazolyl, oxazolyl, 2-oxo-1, 3-dioxole-4
- (22) Mono- or di- to 5-membered heterocyclic monocyclic rubamoyl group; (23) C 6 alkyl monocyclic rubonylamino group which may be substituted by a carboxyl group (eg, acetylamino, propionylamino, etc.) ; (24) a halogen atom, arsenic Dorokishi group, an amino group, - Toromoto, Shiano group, optionally halogenated alkyl group, a mono one or di- CI- 6 Arukiruamino group, C 6 - 14 Ariru group, mono- or di one C 6 - 14 Ariru primary amino groups, C 3 - 8 cycloalkyl group, C - 6 alkoxy group,
- C - 6 alkylthio groups C WINCH 6 alkylsulfinyl group, c - 6 alkylsulfonyl group, a carboxyl group which may be esterified, force Rubamoiru group, Chioka Rubamoiru group, mono- or di -C 6 alkyl Ichiriki Rubamoiru group , Mono-or di-C 6 _ 14 aryl rubamoyl, sulfamoyl, mono or di-
- C 6 alkyl one sulfamoyl group and mono one or di- _C 6 - 14 1 to 3 may be substituted with a substituent C 6 _ 14 Ariruokishi group selected from ⁇ Li one Rusurufu Amoiru group; (25) a halogen atom, Hydroxy group, amino group, etro group, cyano group, C i-6 alkyl group which may be halogenated,
- Canolepoxyl group which may be converted, canolebamoinole group, thio force / rebamoinole group, mono- or di-C-6 alkyl mono-lvamoyl group, monono or di one C 6 - 14 Ari Honoré Ichiriki Rubamoiru group, a sulfamoyl group, mono- or di- C - 6 alkyl one sul Famoiru groups and mono- one or di- one C 6 - 14 to 1 Bareru selected from ⁇ Li one loose sulfamoyl group 3 of which may be substituted with a substituent C 7 - 16 7 Rarukiruokishi group; (12) a halogen atom, arsenic Dorokishi group, an amino group, a nitro group, Shiano group, Nono halogenated C i — 6 alkyl group, mono or di — 6 alkyl monoamino group, C 6 — 14 aryl group, mono
- optionally substituted amino group includes, unless otherwise specified, (1) an optionally substituted C- 6 alkyl group; (2) an optionally substituted C- 6 alkyl group; 2 - 6 alkenyl groups; (3) substituted C 2 _ 6 optionally Arukyuru group; (4) replacement which may C 3 even though one 8 cycloalkyl group; (5) an optionally substituted C 6 - 14 Ariru group; (6) an optionally substituted alkoxy group; (7) an optionally substituted Ashiru group; (8) an optionally substituted Hajime Tamaki (preferably off Lil, pyridyl , thienyl, pyrazolyl, thiazolyl, Okisazoriru); (9) a sulfamoyl group; (10) mono- or di one C - 6 alkyl one sulfamoyl group; etc.
- Tamaki preferably off Lil, pyridyl , thienyl, pyrazolyl, thiazo
- nitrogen-containing heterocycle examples include pyrrolidine, imidazolidine, virazolidine, piperidine, piperazine, morpholine, thiomorpholin, thiazolidine, oxazolidine and the like.
- the term “optionally substituted acyl group” means, unless otherwise specified, a compound represented by the formula: COR 7 , —CO—OR 7 , —SO 2 R 7 , —S OR 7 , —PO (OR 7 ) (OR 8 ), —CO— NR 7 a R 8 a , one CS— NR 7 a R 8 a [wherein R 7 and R 8 are the same or different and are each a hydrogen atom, A hydrocarbon group which may be substituted or a heterocyclic group which may be substituted.
- R 7 a and R 8 a are the same or different connexion, a hydrogen atom, or shows the carbon may be substituted hydrogen group or an optionally substituted heterocyclic group, R 7 a and R 8 a are adjacent May form a nitrogen-containing heterocyclic ring which may be substituted together with the nitrogen atom to be substituted.].
- nitrogen-containing heterocycle of R 7 a and R 8 a is formed together with the adjacent nitrogen atom "substituted but it may also have nitrogen-containing heterocycle", for example, at least in addition to carbon atoms as a ring-constituting atom
- nitrogen-containing heterocycle for example, at least in addition to carbon atoms as a ring-constituting atom
- examples thereof include a 5- or 7-membered nitrogen-containing heterocyclic ring which contains one nitrogen atom and may further contain one or two hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom.
- the nitrogen-containing heterocycle include pyrrolidine, imidazolidine, virazolidine, and arsenic.
- Peridine, piperazine, morpholine, thiomorpholine, thiazolidine, oxazolidine and the like can be mentioned.
- the nitrogen-containing heterocyclic ring may have one or two substituents at substitutable positions.
- substituents a hydroxy group, halogenated which may be C 6 alkyl group, C 6 _ 14 Ariru group, C 7 - 16 such Ararukiru group.
- substituents a hydroxy group, halogenated which may be C 6 alkyl group, C 6 _ 14 Ariru group, C 7 - 16 such Ararukiru group.
- substituents a hydroxy group, halogenated which may be C 6 alkyl group, C 6 _ 14 Ariru group, C 7 - 16 such Ararukiru group.
- the "optionally substituted acyl group” include formyl group, carboxyl group, carbamoyl group, 6- alkyl mono-lponyl group (eg, acetyl, isobutanoyl, isopentanoyl, etc.), and C 6 alkoxyl group.
- Benzoiru 1 _ naphthoyl, 2-naphthoyl, etc.
- C 7 - 16 Araru kills one carbonyl group (eg phenylene Ruasechiru, 2 Hue El prop noisy Le etc.),
- C 6 - 14 Ariruokishi - carbo - Le group eg Hue - Ruo carboxymethyl Cal Poni Le, naphthyl O alkoxycarbonyl, etc.
- C 7 - 16 Ararukiruokishi one power Ruponiru group eg base Nji Ruo alkoxycarbonyl, Hue phenethyl Ruo propoxycarbonyl - le, etc.
- mono- or di-C i-6 alkyl force Rubamoiru group mono- or di-one C 6 - 14 ⁇ Li one Luca Bruno lever moil group ,
- C 3 _ 8 cycloalkyl Ichiriki Rubamoiru group e.g.
- the “rC-s alkylene group” in the “optionally substituted C- 3 alkylene group” ′ in the present specification is linear or branched, for example, methylene, ethylene, monomethylethylene, propylene and the like. Is mentioned.
- the ⁇ Bok 3 alkylene group, a substitutable position may have 1 to 3 substituents.
- substituents for example halogen atom, arsenic Dorokishi group, an amino group, mono- or di-C Bok 6 alkyl primary amino group, mono- or di-_c 6 _ 14 Ariru amino group, mono- or di-one C 7 - 16 Ararukiru primary amino group, a nitro group, Shiano group, C ⁇ 6 an alkoxy group, an alkylthio group, and the like C Bok 6 alkyl group.
- substituents for example halogen atom, arsenic Dorokishi group, an amino group, mono- or di-C Bok 6 alkyl primary amino group, mono- or di-_c 6 _ 14 Ariru amino group, mono- or di-one C 7 - 16 Ararukiru primary amino group, a nitro group, Shiano group, C ⁇ 6 an alkoxy group, an alkylthio group, and the like C Bok 6 alkyl group.
- the "ring” formed by R 1 and R 2 together with the carbon atom to which they are bonded is, for example, one or two ring members other than carbon atoms selected from nitrogen, sulfur and oxygen atoms. 5 to 5 heteroatoms
- 8-membered rings are included.
- Preferred examples of such a ring include 5- to 8-membered hydrocarbon rings such as benzene, dihydrobenzene, and tetrahydrobenzene; pyrroline, virazoline, pyridine, dihydropyridine, tetrahydropyridine, pyrimidine, and dihydropyridine.
- 5- to 8-membered heterocycles such as hydropyrimidine, tetrahydropyrimidine, thiophene, dihydrothiophene, furan, dihydrofuran, pyran, dihydropyran, azepine and oxazepine. .
- the compound of the present invention represented by the formula (I) (hereinafter, may be abbreviated as compound (I)) and a salt thereof will be described.
- X in the formula (I) represents S or O.
- X is preferably S.
- R 1 and R 2 in formula (I) are the same or different and each is a hydrogen atom, an optionally substituted C 6 - 14 Ariru group, be heterocyclic group or substitution may be substituted It represents a good Ci- 6 alkyl group, or R 1 and R 2 are linked together to form a ring with the carbon atom to which they are attached.
- R 1 and R 2 respectively are preferably a hydrogen atom, an optionally substituted C 6 - shows a 14 Ariru group, a heterocyclic group or a halogenated which may be C 6 alkyl group.
- R 1 is preferably a hydrogen atom
- R 2 is preferably an optionally substituted C 6 ′ 14 aryl group or an optionally halogenated alkyl group, more preferably an optionally substituted C 6 6 _ 14 reel group.
- one 14 Ariru group is preferably substituted by halogen atom, 1 to 3 substituents selected from halogenated may CI- 6 alkyl group also Ji may 6 - 14 Ariru group (preferably Hue - Le) Ru der.
- E in the formula (I.) is one V ⁇ _N (R 5 ) one W 2 —, -W ⁇ CH (R 6 ) one O—W 2 one, and -W'-O-CH (R 6 ) —W 2 —, -W 1 -S (O) n_W 2 — or one W 1 -CH (R 6 ) -W 2- (W 1 and W 2 are the same or different and may be a bond or substituted C represents an alkylene group, R 5 and R 6 represent an optionally substituted heterocyclic group or an optionally substituted hydrocarbon group, and n represents 1 or 2. However, when X is S, R 5 and R 6 are not C— 6 alkyl groups.), Preferably one ⁇ —N (R 5 ) —W 2 — or one W 1 —S (O) nW 2 —
- E is more preferably one W 1 —N (R 5 ) one — (W ⁇ W 2 and R 5 are as defined above.
- R 5 is preferably an optionally substituted hydrocarbon group, more preferably an optionally substituted hydrocarbon group. Also it is showing a good C 7- 16 Ararukiru group. However, when X is S, R 5 is not a Ci- 6 alkyl group. ).
- R 5 include (1) a halogen atom and Ji E ⁇ to 1 selected from an alkyl group of three may be substituted with a substituent ⁇ 7 - 16 Ararukiru group (preferably benzyl, phenethyl , 3-phenylpropyl), and
- Ci- 6 alkyl group which may be substituted with 1 to 3 substituents selected from the group consisting of R 1, R 6 and R 5 are not C ⁇ alkyl groups when X is S.
- R 5 is preferably a halogen atom and C i-to 1 selected from e group 3 may be substituted with a substituent C 7 - 6 is an aralkyl group.
- E include: 1) one W 1 —N (R 5 ) one W 2 — (W 1 is a bond, W 2 is a C 3 alkylene group (preferably methylene), and
- R 5 is (1) a halogen atom and C i-6 to 1 is selected from alkyl groups of three location may be substituted with substituent C 7 - 16 Ararukiru group (preferably benzyl, Hue Nechiru, 3- Hue -Propyl) or
- W 1 may be substituted with a bond and W 2 may be substituted with a 6 alkyl group — 3 alkylene group (preferably methylene), and n is 1 or 2 Is shown).
- the ring S 1 in the formula (I) may be substituted — a benzene which may further have a substituent selected from a 6 alkyl group, an optionally substituted C 16 alkoxy group and a halogen atom.
- Ring S 1 preferably represents a benzene ring or a pyridine ring, more preferably a benzene ring.
- R 3 and R 4 in the formula (I) are the same or different and each represents a hydrogen atom, a halogen atom ′, an optionally substituted Ci-6 alkyl group or an optionally substituted Ci-6 alkoxy group. And preferably a hydrogen atom or a halogen atom (preferably a fluorine atom).
- R 9 and R 1 (3 are the same or different and each represent a hydrogen atom, a halogen atom or an alkoxy group, preferably a hydrogen atom or a halogen atom (preferably a fluorine atom), more preferably Shows a hydrogen atom.
- R in the formula (I) represents an optionally substituted hydroxy group or an optionally substituted amino group, preferably represents an optionally substituted hydroxy group, and more preferably represents a hydroxy group or Ci-6 represents an alkoxy group. Of these, a hydroxy group is preferred.
- R 1 and R 2 are the same or different and each represents (1) a hydrogen atom
- heterocyclic group preferably pyridyl
- W 1 and W 2 equal or different, bond or CI- 3 alkylene group (preferably, W 1 is a bond, and W 2 is ⁇ Bok 3 alkylene group (preferably methylcarbamoyl Ren)).
- R 5 is (1) a halogen atom and C ⁇ 6 to 1 is selected from an alkyl group optionally substituted with 1-3 location substituent C 7 - 16 7 aralkyl group (preferably benzyl, Hue Nechiru, 3- off Enylpropyl), or
- R 3 and R 4 are the same or different and each is a hydrogen atom or a halogen atom; ring S 1 is a benzene ring;
- R 9 and R 1 Q are hydrogen atoms
- R is a hydroxy group or a —6 alkoxy group (preferably a hydroxy group).
- R 1 and R 2 are the same or different and each represents (1) a hydrogen atom
- a halogen atom, to 1 Ru is selected from halogenated or may be CI- 6 alkyl group may be substituted with 1-3 substituents Ji 6 - 14 Ariru group (preferably Hue - Le),
- E is 1) —W 1 — N (R 5 ) one W 2 —,
- W 1 and W 2 are the same or different and each is a bond or an alkylene group (preferably, W 1 is a bond, and W 2 is a C 3 alkylene group (preferably, methylene));
- R 5 may be substituted with 1 to 3 substituents selected from (1) halogen atom and C i-6 alkyl group. 7 — 16 aralkyl group (preferably benzyl, phenethyl, 3-phenyl) -Propyl) or
- Ku has also be one 3 alkylene group (preferably with 'with the substituent at bond or C ⁇ e alkyl group, W 1 is a bond, and W 2 is - 6 C-3 alkylene group (preferably methylene) which may be substituted with an alkyl group),
- n 1 or 2;
- R 3 and R 4 are the same or different and each is a hydrogen atom or a halogen atom (preferably a fluorine atom);
- Ring S 1 is a benzene ring or a pyridine ring (preferably a benzene ring);
- R 9 and R 1 Q are the same or different and are a hydrogen atom or a halogen atom (preferably-is a fluorine atom);
- Examples of the salt of compound (I) include metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids.
- Preferred examples of the metal salt include, for example, alkali metals such as sodium salt and potassium salt. Salts; alkaline earth metal salts such as calcium salts, magnesium salts, and barium salts; aluminum salts and the like.
- salts with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N , N, dibenzylethylenediamine and the like.
- salts with inorganic acids include, for example, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- Preferred examples of the salt with an organic acid include, for example, formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesnolefonic acid, benzenesulfonate, p—Salts with toluenesulfonic acid and the like.
- Preferable examples of the salt with a basic amino acid include, for example, salts with arginine, lysine, or-tin
- preferable examples of the salt with an acidic amino acid include, for example, aspartic acid, dartamic acid, and the like. And salts thereof.
- a metal such as an alkali metal salt (eg, sodium salt, potassium salt, etc.) or an alkaline earth metal salt (eg, calcium salt, magnesium salt, barium salt, etc.) Salt
- an inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, or phosphoric acid
- acetic acid or phthalic acid Salts with acids organic acids such as fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid and p-toluenesulfonic acid are preferred.
- a prodrug of compound (I) and a salt thereof is a compound that is converted into compound (I) by a reaction with an enzyme or stomach acid under physiological conditions in vivo, that is, enzymatically causes oxidation, reduction, hydrolysis, or the like.
- Examples of the prodrug of the compound (I) include compounds in which the amino group of the compound (I) is acylated, alkylated, or phosphorylated (for example, the amino group of the compound (I) is icosanoylated, araerylated, pentylamino).
- carboxy group is C i- 6 alkyl ester, phenyl ester, thioloxymethyl ester, dimethylaminomethyl ester, bivaloyloxymethyl ester, ethoxycarbonyloxyethyl ester, phthalidinole ester , (5-Methyl-2-oxo-1, 3-Dioxolen-4-yl) And carboxy groups of compound (I) such as methyl, ethyl and tert-butyl.
- a compound esterified with a Ci- 6 alkyl group is preferably used. These compounds are prepared by a method known per se.
- the prodrug of compound (I) can be prepared under physiological conditions as described in Hirokawa Shoten, 1990, “Development of Pharmaceuticals,” Vol. 7, Molecular Design, pp. 163-198. (I) may be changed.
- each symbol in the following reaction formulas has the same meaning as described above unless otherwise specified. Further, each compound in the reaction formula may form a salt, and examples of the salt include those similar to the salt of compound (I).
- the product in each step in the reaction scheme, can be used as is in the reaction mixture or as a crude product in the next reaction. However, it can be isolated from the reaction mixture according to a conventional method, and can be separated by a usual separation method (eg, It can be easily purified by recrystallization, distillation, chromatography, etc.).
- the amount of the solvent used in the production of each compound is not particularly limited as long as the reaction mixture can be stirred.
- Compound (I) can be produced, for example, according to the method represented by the following reaction formula 1 or the like or a method analogous thereto.
- Compound (I) and compound (1-1) can be produced by subjecting a compound obtained by reacting compound (II) and compound (II) to a hydrolysis reaction, if desired.
- reaction between compound (II) and compound (III) is, for example, the Mitsunobu reaction (synthesis
- R of compound (II) used in step A is preferably a substituted hydroxy group or an optionally substituted amino group.
- the compound (II) and the compound (III) are converted into azodicarboxylates such as getyl azodicarboxylate, diisopropyl azodicarboxylate, and 1, (-(azodicarbonyl) dipiperidine, and phosphines such as triphenylphosphine and tributylphosphine. Reaction in the presence of a class.
- the amount of compound (III) to be used is about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (II).
- the amount of the "azodicarpoxylates” and “phosphines” is about 0.5 to about 5 mol, preferably about 1 mol, per 1 mol of the compound ( ⁇ ), respectively. About 2 moles.
- the reaction of step A is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds.
- ethers such as getyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxetane
- benzene Aromatic hydrocarbons such as toluene
- saturated hydrocarbons such as cyclohexane and hexane
- Amides such as 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone; cyclic ureas and amides; dichloromethanes, chloroforms such as chloroform, and hydrogenated hydrocarbons; acetonitrile, propioni -Nitriles such as tolyl
- the reaction time of Step A is usually about 5 minutes to about 48 hours, preferably about 10 minutes to about 24 hours.
- the reaction temperature of Step A is usually about 120 to about 200 ° C, preferably about 0 to about 100 ° C.
- the R-substituted hydroxy group or the optionally substituted amino group (preferably a methoxy group, an ethoxy group, a tert-butoxy group, an isopropoxy group, etc.)
- the compound (C) is a C 6 alkoxy group
- the compound (I) is subjected to a hydrolysis reaction to produce a compound of the compound (I) wherein R is a hydroxy group, that is, the compound (1-1) (Step B).
- the hydrolysis reaction is performed according to a conventional method using an acid or a base.
- the acid include mineral acids such as hydrochloric acid and sulfuric acid; Lewis acids such as boron trichloride and boron tribromide; and organic acids such as trifluoroacetic acid and P-toluenesulfonic acid.
- the Lewis acid can be used in combination with a thiol or a sulfide.
- Examples of the base include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, and potassium hydroxide; alkaline earth metals such as barium hydroxide; alkali metal carbonates such as sodium carbonate and potassium carbonate; sodium methoxide; Na Alkali metal alkoxides such as thorium ethoxide and potassium tert-butoxide; organic bases such as triethylamine, imidazole, and formamidine are used.
- the amount of these acids and bases to be used is about 0.5-10 mol, preferably about 0.5-6 mol, per 1 mol of compound (I).
- the hydrolysis reaction is performed without a solvent or using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds.
- alcohols such as methanol, ethanol, and propanol
- aromatic hydrocarbons such as benzene and toluene
- saturated hydrocarbons such as cyclohexane and hexane.
- Hydrocarbons organic acids such as formic acid and acetic acid; ethers such as tetrahydrofuran, dioxane and 1,2-dimethoxyethane; amides such as ⁇ , ⁇ _.dimethylformamide and ⁇ , ⁇ -dimethylacetamide Cyclic ureas and amides, such as 1,3-dimethyl-2-imidazolidinone and ⁇ , -methylpyrrolidone; halogenated hydrocarbons, such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane Ketones such as acetone and methyl ethyl ketone; sulfoxides such as dimethyl sulfoxide; solvents such as water; Or a mixed solvent thereof is preferred.
- organic acids such as formic acid and acetic acid
- ethers such as tetrahydrofuran, dioxane and 1,2-dimethoxyethane
- the reaction time of step (2) is usually 10 minutes to 60 hours, preferably 10 'minutes to 12 hours.
- the reaction temperature in step ⁇ is usually 110 to 200 ° C, preferably 0 to 120 ° C.
- Compounds (II) and (III) used in Reaction Formula 1 are easily commercially available. It can be obtained, and can also be produced according to a method known per se or a method analogous thereto.
- the "leaving group" represented by L includes, for example, a halogen atom such as a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom; for example, a halogen atom such as methanesulfonyloxy, ethanesulfonyloxy, and trichloromethanesulfonyloxy. May be
- the “optionally substituted arylsulfo-oxy group” include c- 6 alkyl groups such as methyl and ethyl; 6 alkoxy groups such as methoxy and ethoxy; and the like.
- C e- i which may have 1 to 3 substituents selected.
- Arylsulfonyloxy groups eg, phenylsulfonyloxy, naphthylsulfonyloxy, etc.
- Specific examples include phenylsulfonyloxy, m-trophenylsulfoninoleoxy, and p-toluenesulfonyloxy. No.
- the “optionally substituted hydrocarbon group” represented by R x has the same meaning as the aforementioned “optionally substituted hydrocarbon group”, among which, for example, methyl, ethyl, tert-butyl, isopropyl, etc.
- the alkyl group of is preferred.
- compound (VI-1) is produced by reacting compound (V) with compound (IV) (step).
- Step C is carried out using a solvent inert to the reaction without solvent.
- a solvent is not particularly limited as long as the reaction proceeds.
- amides such as ⁇ , ⁇ -dimethylformamide and ⁇ , ⁇ -dimethylacetamide; 1,3-dimethyl-2-amine Cyclic ureas and amides such as imidazolidinone and ⁇ -methylpyrrolidone; sulfoxides such as dimethyl sulfoxide; aromatic hydrocarbons such as benzene and toluene; saturated hydrocarbons such as cyclohexane and hexane; Ethers such as 1 ⁇ diisopropinole 1 ⁇ , dipheninoleate ⁇ , tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxetane; halogenated carbonization such as dichloromethane, chloroform Hydrogens: Solvents such as esters such as methyl a
- the reaction of Step C is performed in the presence of a base, if desired.
- a base examples include alkali metals such as metal sodium and metal hydride; metal hydrides such as sodium hydride; organolithium reagents such as butyllithium; triethylamine, tripropylamine, triptylamine, n-ethyldiisopropylamine.
- Tertiary amines such as hexyldimethylamine, 4-dimethylaminopyridine, ⁇ , ⁇ -dimethylaerin, ⁇ -methylbiperidine, ⁇ -methylpyrrolidine, ⁇ -methylmorpholine; lithium hydroxide, water Alkali metal hydroxides such as sodium oxide, potassium hydroxide and lithium hydroxide; alkaline earth metal metals such as barium hydroxide; alkali metal carbonates such as sodium carbonate, carbonated carbonate and cesium carbonate; Alkali metal bicarbonate such as hydrogen sodium; sodium acetate; Such as acetic acid salts, such as acid Anmoniumu the like.
- the amount of the base to be used is about 1 to about 20 mol, preferably about 1 to about 10 mol, per 1 mol of compound (IV).
- the reaction can be generally promoted using a metal catalyst.
- a metal catalyst metal complexes having various ligands are used.
- palladium compounds eg: palladium (II) acetate, tetrakis.
- Triphenylphosphine palladium (0), bis (triphenylphosphine chloride) ) Palladium ( ⁇ ), dichlorobis (triethylphosphine) palladium (0), tris (dibenzylideneacetone) dipalladium-1,2,1, bis (diphenylphosphino) 1-1,1'-binaphthyl, palladium (II) acetate and 1,1,1-bis (diphenylphosphino) ) Complexes of phlocene, etc.), Eckel compounds [Examples: Tetrakis (triphenylphosphine) nickel (0), bis (triethylphosphine) nickel (11), bis (triphenylphosphine) nickel ( II), rhodium compounds (eg, tris (triphenylphosphine) rhodium ( ⁇ ⁇ ⁇ ), etc.), cobalt compounds, copper compounds (eg, copper oxide, copper
- a palladium compound, an Eckel compound and a copper compound are preferred.
- the amount of these metal catalysts to be used is about 0.00.001 to 5 mol, preferably about 0.001 to 1 mol, per 1 mol of compound (IV).
- the reaction is preferably performed in an inert gas (eg, argon gas or nitrogen gas) stream.
- the amount of compound (V) to be used is about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (IV).
- the reaction time of Step C is usually about 10 minutes to about 12 hours, preferably about 10 minutes to about 5 hours.
- the reaction temperature of Step C is usually about 130 to about 150 ° C, preferably about 120 to about 100 ° C.
- the compound (II-1) is produced by subjecting the compound (VI-1) to a reduction reaction (Step D).
- the reduction reaction is performed using a reducing agent according to a conventional method.
- the reducing agent include metal hydrides such as aluminum hydride, diisobutylaluminum hydride, and triptyltin hydride; metal hydrogen complex compounds such as lithium aluminum hydride and sodium borohydride; borane tetrahydrofuran complex; Borane complexes such as sulfide complexes; alkylboranes such as texyl borane and disiamyl borane; dipolane; metals such as zinc, aluminum, tin and iron; alkali metals such as sodium and lithium; liquid ammonia (perch reduction); Can be The amount of the reducing agent used is appropriately determined depending on the type of the reducing agent.
- the amount of the metal hydride, metal hydride complex compound, borane complex, alkylporane or diporane to be used is about 1 to about 10 mol, preferably about 1 to 10 mol, per 1 mol of compound (VI-1).
- the amount of W 200 (including the alkali metal used) is about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, relative to compound (VI-1).
- Lewis acids may be used if desired.
- Examples of the “Lewis acids” include aluminum chloride, aluminum bromide, titanium tetrachloride, tin dichloride, zinc chloride, boron trichloride, boron tribromide, boron trifluoride, etc. Is used in an amount of about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (VI-1).
- the reaction in step D is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds, and examples thereof include methanol ethanol and 1-prono. Nonore, 2-prono II. Alcohols such as nonole, tert-petit / leanoleco, etc .; ethers such as getyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethyloxetane; benzene, toluene Aromatic hydrocarbons such as cyclohexane and hexane; Saturated hydrocarbons such as cyclohexane and hexane; amides such as ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ _dimethylacetamide and hexamethylphosphoric triamide Preferred are solvents such as organic acids such as formic acid, acetic
- the reaction time of step D varies depending on the type and amount of the reducing agent used, but is usually about 1 hour to about 100 hours, preferably about 1 hour to about 50 hours.
- the reaction temperature of Step D is usually about ⁇ 20 to about 120 ° C., preferably about 0 to about 80 ° C.
- reaction formula 3 Reaction formula 3
- the leaving group represented by L 1, exemplified as the aforementioned L - include those, a chlorine atom among a halogen atom such as a bromine atom.
- the reaction in step (2) is carried out without a solvent or using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds.
- alcohols such as methanol, ethanol, 1-propanol, 2_propanol and ter-butyl alcohol
- N N-dimethylformamide
- Amides such as N, N-dimethylacetamide
- Cyclic ureas and amides such as 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone
- Aromatic hydrocarbons such as benzene and toluene
- Saturated hydrocarbons such as hexane and hexane
- ethers such as getyl ether, di-sopropionate ethere, diphenolenate ethere, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxetane
- dichloromethane Halogenated hydrocarbons such as
- Step E is performed in the presence of a base, if desired.
- a base if desired.
- examples of the ⁇ base '' include triethylamine, tripropylamine, tributylamine, N-ethylethylisopropylamine, cyclohexyldimethylamine, and 4-dimethylaminopyridine.
- Tertiary amines such as ⁇ , ⁇ -dimethinorea diphosphorus, ⁇ -methylbiperidine, ⁇ -methylpyrrolidine, ⁇ -methylmorpholine; sodium hydroxide, hydroxylase, hydroxide
- Alkali metal hydroxides such as lithium
- alkaline earth metal hydroxides such as barium hydroxide
- alkali metal carbonates such as sodium carbonate, potassium carbonate and cesium carbonate
- alkali metal hydrogen carbonates such as sodium hydrogen carbonate; sodium acetate, ammonium acetate And the like.
- These bases are used in an amount of about 1 to about 20 mol, preferably about 1 to about 10 mol, per 1 mol of compound (VII).
- the amount of compound (VI II) to be used is about 0.3 to about 10 mol, preferably about 0.5 to about 2 mol, per 1 mol of compound (VI I).
- the reaction time of Step E is usually about 10 minutes to about 12 hours, preferably about 10 minutes to about 5 hours.
- the reaction temperature of Step E is usually about 130 to about 200 ° C, preferably about 1 to 20 to about 150 ° C.
- the compound (V) obtained by the reaction in Step E is usually isolated and purified by an appropriate separation means (eg, recrystallization, distillation, chromatography, etc.), and then the next reaction (described above) Although used in step C), the isolation and purification step may be omitted in some cases, and the reaction mixture containing compound (V) obtained in this step E may be used as it is in the next step C.
- step E is performed using a solvent that is used without a solvent and an inert solvent for step C.
- Such solvents include amides such as N, N-dimethylformamide and ⁇ , ⁇ -dimethylacetamide; cyclic ureas such as 1,3-dimethyl-2-imidazolidinone and ⁇ -methylpyrrolidone; Amides; Aromatic hydrocarbons such as benzene and toluene '; Saturated hydrocarbons such as cyclohexane and hexane; Getyl ether, diisopropinole ether, dipheninole ether, tetrahydrofuran, 1,4 Ethers such as -dioxane and 1,2-dimethoxetane; halogenated hydrocarbons such as dichloromethane and chloroform; solvents such as methyl acetate, ethyl acetate, and esters such as ethyl acetate, and mixed solvents thereof. preferable.
- amides such as N, N-dimethylformamide and ⁇ ,
- the compound represented by the formula (IX) is hereinafter abbreviated as compound (IX).
- the “leaving group” for L 2 those exemplified for the aforementioned L can be mentioned.
- compound (1-2) is produced by reacting compound (V) with compound (IX) (Step F).
- the reaction in Step F is performed without a solvent or using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds.
- amides such as ⁇ , ⁇ -dimethylformamide and ⁇ , ⁇ -dimethylacetamide; 1,3-dimethyl_2-imidazolidinone Cyclic ureas and amides such as -methylpyrrolidone; sulfoxides such as dimethyl sulfoxide; aromatic hydrocarbons such as benzene and toluene; saturated hydrocarbons such as cyclohexane and hexane; , Diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; ethers; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride; methyl acetate, acetate Solvents such as e
- Step F The reaction of Step F is performed in the presence of a base, if desired.
- a base As the “base”, What was illustrated in the said process c is used. The amount of these bases used depends on the compound
- the reaction can be promoted using a metal catalyst as in step c.
- the amount of the metal catalyst to be used is about 0.00000-1-5 mol, preferably about 0.001-1-1 mol, per 1 mol of compound (II).
- the amount of compound (V) to be used is about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (II).
- a reaction mixture containing the compound (V) obtained by the reaction in the above step 2 can be used as it is. Step ⁇ in this case is performed using a solvent inert to step F.
- the reaction time of Step F is usually about 10 minutes to about 12 hours, preferably about 10 minutes to about 5 hours.
- the reaction temperature of Step F is usually about _30 to about 150 ° C, preferably about 120 to about 100 ° C.
- a substituted hydroxy group or an optionally substituted amino group (preferably a methoxy group, an ethoxy group, a tert-butoxy group, an isopropoxy group, etc.)
- the compound (1-2) is a C ⁇ s alkoxy group
- the compound (1-2) is subjected to a hydrolysis reaction to obtain a compound (1-2) in which R is a hydroxy group, ie, the compound (1- 3) can be manufactured (Step G).
- the hydrolysis reaction is carried out in the same manner as in the step B in the reaction formula 1.
- the compound (I- 2 ) used in Step G of Reaction Scheme 4 is usually produced by Step F and then isolated and purified by an appropriate separation means (eg, recrystallization, distillation, chromatography, etc.). In some cases, this isolation and purification step is omitted, and the reaction mixture containing the compound (1-2) obtained in Step F can be directly used in the next Step G.
- the hydrolysis reaction in step G is preferably performed using a base.
- the hydrolysis reaction using a base can be carried out by adding an appropriate base and a solvent, if necessary, to the obtained reaction mixture containing the compound (1-2) after Step F is completed. If an excess base is used in step F, this salt Depending on the group, the hydrolysis reaction in step G may proceed, and the compound (1-3) may be obtained without any special additional operation.
- Compound (IX) used in this reaction scheme 4 can be produced by a method known per se or a method analogous thereto.
- compound (IX) can be produced by the method represented by the following reaction formula 5.
- reaction scheme 5 compound (IX) is produced by reacting compound (II) with compound (X) (step H). This reaction is performed in the same manner as in Step A in the aforementioned Reaction Scheme 1.
- R of the compound (II) used in the step H is preferably a substituted hydroxy'oxy group or an optionally substituted amino group.
- Compound (X) used in Reaction Scheme 5 can be easily obtained as a commercial product, and can also be produced according to a method known per se or a method analogous thereto.
- Examples of the substituent in the “optionally substituted alkyl group” ′ represented by R y include the substituents exemplified as the aforementioned “optionally substituted Ci- 3 alkylene group”.
- R y is 2 alkyl group which may be substituted, if W 3 is a "substituted methylene group optionally", R y is substituted When W 3 is an “optionally substituted ethylene group”, R y is a hydrogen atom.
- the reduction reaction is generally performed using a reducing agent according to a conventional method.
- a reducing agent include metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride; sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, and the like.
- Metal-hydrogen complex compounds such as porane tetrahydrofuran complex and porane dimethyl sulfide complex; alkylboranes such as texyl borane and disiamyl borane; diporane; metals such as zinc, aluminum, tin and iron; sodium, lithium and the like Alkali metal Z liquid ammo air (perch reduction).
- the amount of the reducing agent used is appropriately determined depending on the type of the reducing agent.
- the amount of the metal hydride or metal hydride complex compound to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (XI), respectively.
- the amount of diborane to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (XI), and the use of metals (including alkali metals used in perch reduction)
- the amount is about 1 to about 20 equivalents, preferably about 1 to about 5 equivalents, per 1 mol of compound (XI).
- the reduction reaction can be carried out by a hydrogenation reaction.
- a catalyst such as palladium carbon, platinum dioxide, Raney nickel, or Raney cobalt is used.
- the amount of the catalyst to be used is about 5 to about 1000% by weight, preferably about 10 to about 300% by weight, per 1 mol of compound (XI).
- the hydrogenation reaction can also be carried out by using various hydrogen sources instead of gaseous hydrogen.
- a hydrogen source for example, formic acid, ammonium formate, triethylammonium formate, sodium phosphinate, hydrazine and the like are used.
- the amount of the hydrogen source to be used is about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (XI).
- the reaction of Step I is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds, and examples thereof include methanol, ethanol, 1-propanol, 2-propanol and tert-butyl alcohol.
- alcohols such as getinoleatenore, diisopropizoleatenole, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxetane; aromatic hydrocarbons such as benzene and toluene Saturated hydrocarbons such as cyclohexane and hexane; amides such as N, N-dimethylformamide, N, N-dimethylacetamide and hexamethylphosphoric triamide; formic acid, acetic acid, propanoic acid, Solvents such as organic acids such as trifluoroacetic acid and methanesulfonic acid, and mixed solvents thereof are preferable.
- ethers such as getinoleatenore, diisopropizoleatenole, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxetane
- Step 2 the compound (VI-2) is subjected to a reduction reaction to produce a compound (III-2) (Step: The reduction reaction is carried out in the same manner as in Step D in the aforementioned Reaction Formula 2.
- the reduction reaction is carried out in the same manner as in Step D in the aforementioned Reaction Formula 2.
- --Reaction Compounds (XI) and (XII) used in Formula 6 can be easily obtained as commercial products, and can also be produced according to a method known per se or a method analogous thereto.
- the compound of the formula (II I-3) (compound (I II-3)) which is —CH (R 6 ) —0—W 2 — It is manufactured by the method indicated by. '
- the compound (VI-3) is produced by reacting the obtained compound (XIV) with the compound (XV) (step L).
- This reaction is appropriately selected depending on the type of W 2 in compound (XV).
- the compound (VI-3) in which W 2 is a bond can be produced using the compound (XV) in which L 3 is a hydroxyl group in the same manner as in Step 2 of Reaction Scheme 1.
- (VI-3) can be produced, for example, by reacting a compound (XV) wherein L 3 is a leaving group exemplified as L above with a compound (XIV) in the presence of a base, if desired. .
- the reaction is carried out, for example, in the same manner as in Step C in Reaction Scheme 2. Further, in Reaction Scheme 7, by subjecting (VI-3) to a reduction reaction, the compound (XV) wherein L 3 is a leaving group exemplified as L above with a compound (XIV) in the presence of a base, if desired. .
- the reaction is carried out, for example, in the same manner as in Step C in Reaction Scheme 2. Further, in Reaction Scheme 7, by subjecting (VI-3) to a reduction reaction, the compound (XV) wherein L 3 is a leaving group exemplified as L above with a compound (XIV) in the presence of a base, if desired. .
- the reaction is carried out, for example, in the same manner as
- triarylphosphines represented by PA r 3 for example triflates E - Le phosphine and the like are used.
- a phosphonium salt of the compound (XVI) is produced by reacting the compound (XVI) with a triarylphosphine, and the phosphonium salt is reacted with the compound (XIII) to give the compound (XVI I) is manufactured (Step N).
- the reaction between compound (XVI) and triarylphosphines is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds, and examples thereof include getyl ether, diisopropyl ether, and diisopropyl ether.
- Ethers such as phenyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxetane; aromatic hydrocarbons such as benzene and toluene; saturated hydrocarbons such as cyclohexane and hexane; N Amides such as N, N-dimethylformamide, N, N-dimethylacetamide and hexamethylphosphoric triamide; cyclic ureas and amides such as 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone Or a mixed solvent thereof.
- the amount of the triarylphosphine to be used is about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (XVI).
- step N it is also possible to isolate the phosphonium salt of compound (XVI). Without performing the isolation operation, the compound (XIVI) is converted to a reaction solution containing the phosphonium salt of compound (XVI). )), The reaction can be performed continuously.
- the reaction of the compound (XII) with the phospho-pam salt of compound (XVI) is carried out using, for example, the Wittig reaction.
- the reaction is usually performed in the presence of a base.
- the base include metal hydrides such as sodium hydride; triethylamine, tripropylamine, triptylamine, N-ethyldiisopropylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N ′, N Tertiary amines such as dimethylaniline, N-methylbiperidine, N-methylpyrrolidine, and N-methylmorpholine; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide; water such as barium hydroxide Alkaline earth metal oxides; alkali metal carbonates such as sodium carbonate, potassium carbonate and cesium carbonate; alkali metal hydrogen carbonates such as sodium hydrogen carbonate; acetates such as sodium acetate, am
- the amount of compound (XIII) to be used is about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (XVI) or a phosphonium salt thereof.
- the reaction between the phosphonium salt of compound (XVI) and compound (XI II) is inactive in the reaction. It is advantageous to carry out using a neutral solvent.
- a neutral solvent is not particularly limited as long as the reaction proceeds, and examples thereof include ethers such as getyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; Aromatic hydrocarbons such as benzene and benzene; saturated hydrocarbons such as cyclohexane and hexane; N, N-dimethylformamide, ⁇ , ⁇ -dimethylacetamide, hexamethylphosphoric triamide And amides such as 1,3-dimethyl-2-imidazolidinone and 1-methylpyrrolidone, and mixed solvents thereof.
- the compound (VI-4) is produced by subjecting the compound (XVI I) to a hydrogenation reaction (Step 0).
- the hydrogenation reaction is carried out in the same manner as the hydrogenation reaction exemplified in Step I of Reaction Scheme 6 above.
- Step ⁇ the compound (VI-4) is subjected to a reduction reaction to produce a compound (II-4) (Step ⁇ ).
- the reduction reaction is carried out in the same manner as in Step D in Reaction Scheme 2 described above.
- Compound (XVI) used in Reaction Scheme 8 can be produced by a method known per se or a method analogous thereto. '
- the "leaving group" represented by L 5, Ru include those exemplified as the aforementioned L.
- compound (1-4) can be produced by subjecting compound (XX) to an oxidation reaction (step R).
- This reaction is carried out using an oxidizing agent according to a conventional method.
- the oxidizing agent include peracids such as hydrogen peroxide, peracetic acid, perbenzoic acid, and metabenzo-perbenzoic acid; sodium metaperiodate, hydroperoxide, ozone, selenium dioxide, chromic acid, and dinitrogen tetroxide.
- This reaction is advantageously performed using a solvent inert to the reaction.
- a solvent is not particularly limited as long as the reaction proceeds.
- alcohols such as methanol, ethanol, and propanol
- ethers such as dimethyl ether, tetrahydrofuran.
- the reaction time varies depending on the type and amount of the oxidizing agent used, but is usually 5 minutes to 48 hours, preferably 10 minutes to 12 hours.
- the reaction temperature is usually from 140 to 200 ° C, preferably from 110 to 120 ° C.
- a substituted hydroxy group or an optionally substituted amino group preferably a methoxy group, an ethoxy group, a tert-butoxy group, an isopropoxy group, etc.
- the hydrolysis reaction is carried out in the same manner as in the step B in the reaction formula 1.
- Each compound produced according to the above reaction formulas 1 to 9 can be easily purified by ordinary separation means (eg, recrystallization, distillation, chromatography, etc.). Depending on the method, they can be converted to their salts or prodrugs.
- a protecting group such as generally used in peptide chemistry is used for these groups.
- the target compound can be obtained by removing the protecting group as necessary after the reaction, if necessary.
- Examples of the protecting group for an amino group include a formyl group and an optionally substituted C 6 alkyl monopropyl group (for example, acetyl, ethylcarbyl, etc.), a phenylcarbonyl group, — 6- Alkyloxycarbonyl groups (for example, methoxy canoleponinole, ethoxy canoleponinole, tert-butoxycarbonole (Boc), etc.), aryloxycarbonyl (A 1 oc) group, phenyl Okishikarubo group, Furuore - methyl O butoxycarbonyl (F moc) group, C 7 - 1 0 Araru kill one carbo - Le group (e.g., benzylcarbonyl),.
- C 6 alkyl monopropyl group for example, acetyl, ethylcarbyl, etc.
- a phenylcarbonyl group for example, methoxy canole
- Aralkyl monooxycarbonyl group for example, benzyloxycarbonyl ⁇ (Z) etc.
- C 7 - 1 0 Ararukiru group e.g., benzyl, etc.
- trityl group phthaloyl group, dithiasuccinoyl Asukushinoiru group or N, N-dimethyl aminomethylene group.
- substituents include a phenyl group, a halogen atom, a Ci-6 alkyl-carbonyl group (for example, acetyl, ethylcarbonyl, butylcarbonyl, etc.), an alkoxy group which may be substituted by a nitrogen atom (for example, Methoxy, ethoxy, trifluoromethoxy, etc.), nitro group, etc. are used, and the number of substituents is about one to three.
- a phenyl group for example, acetyl, ethylcarbonyl, butylcarbonyl, etc.
- an alkoxy group which may be substituted by a nitrogen atom for example, Methoxy, ethoxy, trifluoromethoxy, etc.
- nitro group etc.
- Examples of the carboxyl-protecting group include a C- 6 alkyl group, an aryl group, a benzyl group, a phenyl group, a phenyl group, a trityl group and a trialkylsilyl group, each of which may have a substituent. .
- substituents include a halogen atom, formyl group, C ⁇ 6 alkyl Ichiriki Lupo - Le group (e.g., Asechiru, Echiruka Ruponiru and butyl carbonyl), is a C one even though 6 alkoxy substituted with a halogen atom Groups (eg, methoxy, ethoxy, trifluoromethoxy, etc.), nitro groups, etc. are used, and the number of substituents is about one to three.
- Examples of protecting groups for human Dorokishi group may have a substituent, respectively, C - 6 alkyl group, C 7 - 2.
- An aralkyl group eg, benzyl, trityl, etc.
- a formyl group e.g., acetyl, ethylcarbonyl, etc.
- a benzoyl group a C—— group.
- Examples include an aralkyl monopropionyl group (eg, benzylcarbyl), a tetrahydrovinylil group, a fural group or a trialkylsilyl group (eg, trimethylsilyl, tert-butyldimethylsilyl, diisopropylpropylsilyl, etc.).
- substituents include a halogen atom, a Ci- 6 alkyl group, a phenyl group, and C ⁇ .
- An aralkyl group eg, benzyl
- a C-6 alkoxy group, an ethoxy group, and the like are used, and the number of substituents is about 1 to 4.
- the protection group of mercapto includes, for example, the substituents may be respectively alkyl groups, C 6 alkyl Ichiriki Ruponiru group (e.g., Asechiru, etc. Echiru carbonyl), c 7 _ 2 0 Ararukiru group (e.g. Benzyl, trityl and the like).
- the substituent a halogen atom, an alkyl group, phenyl group, c 7 - 1 0 Ararukiru group (e.g., benzyl, etc.), ⁇ Bok 6 alkoxy Si and nitro groups are used, and the number of substituents is about 1 to 4.
- a method for removing the protecting group a method known per se or a method analogous thereto can be used.
- acid, base, reduction, ultraviolet light, hydrazine, phenol-hydrazine, sodium N-methyldithiolrubamate, A method of treating with butylammonium fluoride, palladium acetate, or the like is used.
- the compound (I), other reaction intermediates and the starting compounds thus obtained can be obtained from the reaction mixture by a method known per se, for example, extraction, concentration, neutralization, filtration, distillation, recrystallization, column chromatography, Isolation and purification can be achieved by using thin-layer chromatography, preparative high-performance liquid chromatography (preparative HPLC), medium-pressure preparative liquid chromatography (medium-pressure preparative LC), etc. .
- the salt of the compound (I) can be prepared by a known method, for example, by adding an inorganic acid or an organic acid when the compound (I) is a basic compound, or by adding the compound (I) to an acidic compound. In this case, it can be produced by adding an organic base or an inorganic base.
- optical isomers can exist in compound (I), both of these individual optical isomers and mixtures thereof are, of course, included in the scope of the present invention. It can be optically divided according to a means known per se or can be manufactured individually.
- the compound (I) exists as a constitutive isomer (configuration isomer), diastereomer, conformer, or the like, each of them can be isolated by the above separation and purification means, if desired.
- the compound (I) is in a racemic form, it can be separated into an S-form and an R-form by ordinary optical resolution means.
- Compound (I) may be a hydrate or a non-hydrate.
- Compound (I) may be labeled with an isotope (eg, 3 H, 14 C, 35 S).
- -Compound (I), a salt thereof and a prodrug thereof (hereinafter abbreviated as compound of the present invention)
- GPR40 receptor agonism activity GPR40 receptor agonist activity
- it has few side effects (eg, acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity, etc.)
- it is a safe GPR40 receptor function modulator, preferably a GPR40 agonist. Useful.
- the medicament containing the compound of the present invention has excellent GPR 40 against mammals (eg, mouse, rat, hamster, rabbit, cat, dog, rabbit, hidge, monkey, human, etc.). Since it has a receptor function regulating action, it is useful as an agent for regulating a physiological function involving the GPR40 receptor or a prophylactic / therapeutic agent for a disease-state or disease involving the GPR40 receptor.
- mammals eg, mouse, rat, hamster, rabbit, cat, dog, rabbit, hidge, monkey, human, etc.
- a medicament containing the compound of the present invention is useful as an insulin secretion regulator (preferably an insulin secretagogue), a hypoglycemic agent, a knee) 3 cell protective agent.
- an insulin secretion regulator preferably an insulin secretagogue
- a hypoglycemic agent preferably a hypoglycemic agent
- a knee 3 cell protective agent.
- a medicament containing the compound of the present invention includes, for example, diabetes, impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, uropathic retinopathy, macular edema, hyperlipidemia Disorders, sexual dysfunction, skin disorders, arthropathy, osteopenia, arteriosclerosis, thrombotic disorders, indigestion, memory learning disorders, depression, manic depression, schizophrenia, attention deficit hyperactivity disorder, visual impairment, Appetite dysregulation (eg, bulimia), obesity, hypoglycemia, hypertension, edema, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulinoma, lipotoxicity, knee fatigue, hyperinsulinemia, Cancer (eg, breast cancer, etc.), metabolic syndrome, immune system disease (eg, immunodeficiency, etc.), inflammatory disease (eg, enteritis, arthritis, allergy, etc.), multiple sclerosis, acute kidney Diseases such as diabetes, impaired glucose tolerance, ketosis, acidosis, diabetic
- diabetes includes type 1 diabetes, type 2 diabetes and gestational diabetes.
- hyperlipidemia includes hypertriglyceridemia, hypercholesterolemia, hypoHDLemia, and postprandial hyperlipidemia.
- criteria for diabetes a new criteria was reported by the Japanese Diabetes Association in 1999.
- diabetes is defined as a fasting blood glucose level (glucose concentration in venous plasma) of at least 126 mg / d1 and a 75 g transglucose tolerance test (75 g OGTT)
- glucose concentration in plasma plasma concentration
- blood glucose level glucose level in venous plasma
- diabetes was defined as a fasting blood glucose level (dulcose concentration in venous plasma) of 126 mg Zd 1 or more, and a 75 g transglucose tolerance test 2-hour value (venous plasma concentration). Glucose concentration at 20 OmgZd1).
- impaired glucose tolerance is defined as a fasting blood glucose level (glucose concentration in venous plasma) of less than 126 mg / d1 and a 2-hour glucose glucose load test of 75 g. (Glucose concentration in venous plasma) is 14 OmgZd1 or more and less than 20 OmgZd1. Further, according to the report of the ADA, a state in which the fasting blood glucose level (glucose concentration in venous plasma) is 11 OmgZd 1 or more and less than 126 mg / dl is called IFG (Impaired Fasting Glucose).
- the 2-hour value (glucose concentration in venous plasma) of a 75 g transglucose load test is less than 140 mg / d1.
- the condition is called IFG (Impaired Fasting Glycemia).
- the compounds of the present invention include diabetes, borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) and IFG
- the compounds of the present invention can also prevent the development of diabetes from borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) or IFG (Impaired Fast Ining Glyceraia).
- the compound of the present invention is also useful as a therapeutic agent for sulfonylurea secondary ineffective diabetes, and a sulfonylurea compound or a fast-acting insulin secretagogue does not provide an insulin secretion effect. Even in diabetic patients who cannot obtain a blood glucose lowering effect, they exhibit an excellent insulin secretion effect and a blood glucose lowering effect.
- the sulfonylurea compound includes a compound having a sulfo-lurea skeleton or a derivative thereof, for example, tolptamide, dalibenclamide, daliclazide, --10-chloropropamide, tolazamide, acetohexamide, glyclopyramide , Glimepiride, glipizide, gribuzole and the like.
- sulfonylperrea compounds such as repaglid, senaglinide, nateglinide, And glinide compounds such as mitiglinide or its calcium salt hydrate.
- the medicament containing the compound of the present invention has low toxicity, and the compound of the present invention can be used as such or pharmacologically acceptable according to a method known per se which is generally used as a method for producing a pharmaceutical preparation. After mixing with a carrier to form a pharmaceutical preparation, it can be safely administered orally or parenterally (eg, topically, rectally, intravenously, etc.).
- a carrier e.g., topically, rectally, intravenously, etc.
- Examples of the dosage form of the pharmaceutical preparation include tablets (including sublingual tablets and buccal tablets), capsules (including soft capsules and microcapsules), granules, powders, troches, and syrups.
- Preparations emulsions, suspensions, and other oral preparations; and injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, infusions), external preparations (eg, transdermal preparations) , Ointments), suppositories (eg, rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations 25 (inhalants), and parenteral preparations such as eye drops.
- injections eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, infusions
- external preparations eg, transdermal preparations
- Ointments eg, Ointments
- suppositories eg, rectal suppositories, vaginal suppositories
- pellets eg, nasal preparations, pulmonary preparations 25 (inhalants), and parenteral preparations such as eye
- compositions may be controlled-release preparations such as immediate-release preparations or sustained-release preparations (eg, sustained-release microcapsules).
- the content of the compound of the present invention in the pharmaceutical preparation is from about 0.01 to about 10% of the whole preparation.
- the dose of the compound of the present invention depends on the administration subject, administration route, disease, and disease. For example, when orally administered to an adult diabetic patient (body weight of about 6 O kg), about 0.01 to about 30 rag / kg body weight per 1 S, preferably about 0.1 to About 2 O mgZ kg body weight, more preferably about 1 to about 2 O mg / kg body weight. This dose can be administered in one or several doses a day.
- the above-mentioned pharmacologically acceptable carriers include various organic or inorganic carrier substances commonly used as pharmaceutical materials, such as excipients, lubricants, binders and disintegrants in solid formulations, or liquid Solvents, solubilizing agents, suspending agents, isotonic agents, buffers, soothing agents and the like in the preparations. If necessary, additives such as preservatives, antioxidants, coloring agents, sweeteners, adsorbents, wetting agents and the like can also be used.
- excipient examples include lactose, sucrose, D-mantol, starch, corn starch, crystalline cellulose, light caffeic anhydride and the like.
- lubricant examples include magnesium stearate, calcium stearate, talc, colloid silica and the like.
- Binders include, for example, crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropinoresenololose, hydroxypropizolemethinoresenorelose, polybutylpyrrolidone, starch, sucrose, gelatin, methylcellulose And carboxymethylcellulose sodium.
- Disintegrators include, for example, starch, carboxymethylcellulose, carboxymethinoresenolerose kanoresime, sodium canoleboximethynolestarch, L-hydroxypropinolecellulose and the like.
- solvent examples include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and olive oil.
- solubilizing agent examples include polyethylene glycol, propylene glycol, D-mantol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; Nyl alcohol, polyvinylinolepyrrolidone, carboxymethylcellulose sodium, methinoresenololose, hydroxymethinoresenorelose, .. hydrophilic polymers such as hydroxypropyl cellulose, hydroxypropylcellulose, etc. Is mentioned.
- surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate
- Nyl alcohol polyvinylinolepyrrolidone, carboxymethylcellulose sodium, methinoresenololose, hydroxymethinoresenore
- tonicity agent examples include pudose sugar, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
- buffers such as phosphate, acetate, carbonate, and citrate.
- Examples of the soothing agent include benzyl alcohol and the like.
- preservatives include parahydroxybenzoic acid esters, chlorobutanol, .benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid, ⁇ -tocopherol and the like.
- the coloring agent examples include water-soluble edible tar dyes (eg, edible dyes such as edible red No. 2 and 3, edible yellow No. 4 and 5, edible blue No. 1 and No. 2), water-insoluble lake dyes ( Examples: the water-soluble edible tar dye aluminum salt), heavenly natural colorants (eg, ⁇ -carotene, chlorophyll, redwood) and the like.
- water-soluble edible tar dyes eg, edible dyes such as edible red No. 2 and 3, edible yellow No. 4 and 5, edible blue No. 1 and No. 2
- water-insoluble lake dyes examples: the water-soluble edible tar dye aluminum salt
- heavenly natural colorants eg, ⁇ -carotene, chlorophyll, redwood
- sweetener examples include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
- the compound of the present invention is a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobesity agent, a diuretic agent, a chemotherapeutic agent, an immunotherapy agent, an anti-inflammatory agent, an antithrombotic agent, It can be used in combination with drugs such as osteoporosis drugs, vitamin drugs, anti-dementia drugs, frequent urinary incontinence drugs, and dysuria drugs (hereinafter sometimes abbreviated as drug X). '
- insulin preparations eg, animal insulin preparations extracted from the stomach of pigs and pigs; human insulin preparations genetically synthesized using Escherichia coli and yeast; insulin zinc; protamine insulin Zinc; insulin fragment or derivative (eg, INS-1 etc.); oral insulin preparation, etc., insulin sensitivity enhancer [eg: pioglitazone or a salt thereof (preferably hydrochloric acid) Salt), rosiglitazone or its salt (preferably maleate), reglixane
- insulin preparations eg, animal insulin preparations extracted from the stomach of pigs and pigs; human insulin preparations genetically synthesized using Escherichia coli and yeast; insulin zinc; protamine insulin Zinc; insulin fragment or derivative (eg, INS-1 etc.); oral insulin preparation, etc., insulin sensitivity enhancer [eg: pioglitazone or a salt thereof (preferably hydrochloric acid) Salt), rosiglitazone or its salt (preferably maleate), reglixane
- lebutin resistance improver lebutin resistance improver
- somatostatin receptor agonist TO01 / 25228, 003/42204, W098 / 44921, W098 / 45285, W099 / 22735 etc.
- glu Cokinase activators eg, Ro-28-1675, etc.
- Therapeutic agents for diabetic complications include aldose reductase inhibitors (eg, tolrestat, epanorestat, zenarestat, zoponorestat, fidarestat (SNK-860), AS-3201) , Minalrestat (AR I-509), CT-112, etc., neurotrophic factor and its increasing drugs (eg, NGF, NT-3,
- BDNF neurotrophin production and secretagogues described in TO01 / 14372 (for example, 4- (4-methyl-1-methyl) -2- (2-methyl-1-imidazolyl) -5- [3- (2- Methylphenoxy) pupyl pill] oxazole, etc.) etc.), protein ink "I-C (PKC) inhibitor
- AGE inhibitors eg: ALT—945, pimagedin, pyratoxa-tin, N-phenacylthiazolyl Mbuguchi mid (ALT-7766), EXO-226, ALT-711, pyridorin, pyridoxamine, etc., active oxygen scavengers (eg, lactic acid, etc.), cerebral vasodilators (Eg, tioprid, etc.), somatostatin receptor agonist (BIM23190), apoptosis signal regulatory agent, and ⁇ -1 (ASK-1) inhibitor.
- AGE inhibitors eg: ALT—945, pimagedin, pyratoxa-tin, N-phenacylthiazolyl
- Mbuguchi mid ALT-7766
- active oxygen scavengers eg, lactic acid, etc.
- HMG-CoA reductase inhibitors eg, pravastatin, cinnostatin, ronokustatin, atonorenostatin, funorevastatin, vita pastatin, rospastatin or a salt thereof (eg, sodium salt) for the treatment of hyperlipidemia , Calcium salt, etc.), etc.
- a salt thereof eg, sodium salt for the treatment of hyperlipidemia , Calcium salt, etc.
- Antihypertensive drugs include angiotensin converting enzyme inhibitors (eg, captopril, enalapril, delapril, etc.), angiotensin II receptor antagonists (eg, oral sultans, candesartan cilexetil, eprosanoletane, panoresanoletane, telmisartan, Ilbesartan, olmesartan medoxomil, tasosartan, 1-[[2,-(2,5-dihydro-5-oxo-4H-1,2,4-oxaziazol, 3-yl) bihue Le-4-yl] methyl] -2-ethoxy-1H-benzimidazole-7-carboxylic acid, etc., power norezymjyanenore blocker (eg: manidipine, niedipine, amlodipine, efo-dipine, dicardipine, etc.) ), Clonidine and the
- anti-obesity agents include central anti-obesity drugs (eg, dexfunfunamine, fenfluramine, phentermine, sibutramine, ampuepramine, dexane fuetamine, mazindore, feninolepropanolamine, clovenzolex; MCH Receptor antagonists (eg, SB-568849; SNAP-7941; W001 / 82925 and
- knee lipase inhibitors eg, orlistat, ATL—962, etc.
- ⁇ 3 agonist eg, CL-1 3 624 3, SR—5 8 6 11—A, UL- TG-3 0 7 N AJ-9 6 7 7 N AZ 40 1 40 etc.
- Peptide anorectic drugs eg: lebutin, CNTF (ciliary neurotrophic factor) etc.
- Cholesis Tokyunagost (example) : Lynch tribute, FPL-158489, etc.
- anorectic drugs eg : -57 etc. and the like.
- Diuretics include, for example, xanthine derivatives (eg, sodium nitrate theobalicylate salicylate, calcium theopromine salicylate, etc.), thiazide-based preparations (eg, ethiazide, cyclopenthiazide, trichlormethiazide, hydrochloride thiazide, hydroflumethiazide, Benzyl hydrochloride oral thiazide, penflutide, polythiazide, methyclothiazide, etc., anti-aldosterone preparations (eg, spironolatane, triamterene, etc.), carbonic anhydrase inhibitors (eg, acetazolamide, etc.), chlorbenzene sulphonamide preparations (Eg, chlorthalidone, mefluside, indapamide, etc.), azosemide, isosorbide, ethacrynic acid, piretan
- Chemotherapeutic agents include, for example, alkylating agents (eg, cyclophosphamide, diphosphamide), antimetabolites (eg, meso-trexate, 5-fluorouracil and derivatives thereof), anticancer antibiotics ( Examples: mitomycin, adriamycin, etc.), plant-derived anticancer agents (eg, vincristine, vindesine, taxol, etc.), Cisplatin, carpoplatin, etoposide and the like. Among them, a 5-fluorouracil derivative such as fluron or neoflururon is preferred.
- alkylating agents eg, cyclophosphamide, diphosphamide
- antimetabolites eg, meso-trexate, 5-fluorouracil and derivatives thereof
- anticancer antibiotics Examples: mitomycin, adriamycin, etc.
- plant-derived anticancer agents eg, vincristine, vindes
- immunotherapeutic agents include microorganisms or bacterial components (eg, muramyl dipeptide derivatives, picibanil, etc.), polysaccharides having immunopotentiating activity (eg, lentinan, schizophyllan, krestin, etc.), and genetic engineering techniques.
- Site force-in eg, interferon, interleukin (IL), etc.
- colony-stimulating factor eg, granulocyte colouyu-stimulating factor, erythropoietin, etc.
- IL-1 interleukin
- IL_2 IL — Interleukins
- Interleukins such as 12 are preferred.
- anti-inflammatory drug examples include non-steroid anti-inflammatory drugs such as aspirin, acetaminophen, indomethacin and the like.
- antithrombotic agents include heparin (eg, heparin sodium, heparin calcium, dalteparin sodium, etc.), perfurin (eg, perfarin potassium, etc.), antithrombin drugs (eg, Argatroban, etc.), thrombolytic drugs (eg, urokinase, tisokinase, tiolekinase, alteplase, nateplase, nateplase), monteplase (tnonteplase), nomiteplases, etc.
- Aggregation inhibitors eg, ticlopidine hydrochloride
- cilostazol ci lostazol
- ethyl icosapentate beraprost sodium
- Examples of therapeutic agents for osteoporosis include alfacal cidol, alfacal cidol, calc itriol, enorecatonin, elcatonin, salmon calcitonin salmon, estrio lestrone, and iprifurapon.
- Vitamins agents eg vitamins, vitamin B 12 or the like.
- Antidementia drugs include, for example, tacrine, donepezil, Rivastigmine, galanthamine and the like.
- remedies for pollakiuria and urinary incontinence include, for example, flavoxate hydrochloride, oxybutynin hydrochloride, and propiverine hydrochloride.
- therapeutic agents for dysuria include acetylcholinesterase inhibitors (eg, distigmine and the like).
- drugs that have been shown to improve cachexia in animal models and clinical settings such as cyclooxygenase inhibitors (eg, indomethacin), progesterone derivatives (eg, megestrol acetate), sugars Steroids (eg, dexamethasone.), Methotramide plamides, tetrahydrocannabinols, fat metabolism improvers (eg, eicosapentaenoic acid, etc.), growth hormone, IGF_1, or cachexia Antibodies against factors such as TNF- a , LIF, IL-16, and oncostatin M can also be used in combination with the compound of the present invention.
- cyclooxygenase inhibitors eg, indomethacin
- progesterone derivatives eg, megestrol acetate
- sugars Steroids eg, dexamethasone.
- Methotramide plamides etrahydrocannabinols
- saccharification inhibitors eg, ALT-711 etc.
- nerve regeneration promoters eg, Y-128, VX853, prosaptide, etc.
- antidepressants eg, desibramin, amitripty'lin, imipramine, etc.
- Antiepileptic drugs eg, Lamotrigine, Trileptal, Keppra, Zonek, 'Zonegran, Pregbalin, Precobalin, Harkoseride, Carbamazepine, etc.
- acetylcholine receptor ligands e.g.
- ABT- 594, etc. endothelin receptor antagonists (eg: ABT- 6 2 7, etc.), monoamine uptake inhibitors (e.g., tramadol, etc.), narcotic analgesics Drugs (eg, morphine, etc.), GABA receptor agonists (eg, gyabapentin, gabapentin MR agent, etc.), o; 2 receptor agonists (eg, clonidine, etc.), local analgesics (eg, capsai) Synth), anxiolytics (eg, benzothiazepine), phosphodiesterase inhibitors (eg, sildenafil), dopamine receptor agonists (eg, apomorphine), etc. can also be used in combination with the compounds of the present invention. it can.
- endothelin receptor antagonists eg: ABT- 6 2 7, etc.
- monoamine uptake inhibitors e.g., tramadol, etc.
- the above drug X may be used in combination of two or more kinds at an appropriate ratio.
- the treatment period can be set longer
- the timing of administration of the compound of the present invention and Drug X is not limited, and the compound of the present invention and Drug X may be administered simultaneously to a subject to be administered. It may be administered at a time interval.
- the dose of the drug X may be in accordance with the clinically used dose, and can be appropriately selected depending on the administration subject, administration route, disease, combination, and the like.
- the administration form of the compound of the present invention and the drug X is not particularly limited, as long as the compound of the present invention and the drug X are combined at the time of administration.
- Such administration forms include, for example, (1) administration of a single preparation obtained by simultaneously preparing a compound of the present invention and drug X, and (2) separate administration of the compound of the present invention and drug X separately. (3) Simultaneous administration of the two preparations obtained by formulation using the same administration route, and (3) the time difference of the two administration preparations obtained by separately formulating the compound of the present invention and drug X by the same administration route.
- E is _C3 ⁇ 4 one New (( ⁇ - 6 alkyl group) mono-, over ⁇ - 6 alkyl group) one CH 2 -, one S- CHO ⁇ - 6 alkyl group) one or _CH 2 - CHO ⁇ - 6 alkyl group) -, compound or the salt thereof and,
- X is S
- ring S 1 is optionally substituted C
- E is —W 1 — N (R 5 ) — W 2 —, -W X -CH (R 6 ) one O— W 2 —, —W 1 — O— CH (R 6 ) —W 2 —, one W 1 — S (O) n— W 2 — or one Wi— CH (R 6) -W 2 - (W 1 and W 2 are the same or different
- a bond or substituted ⁇ may 3 alkylene group
- R 5 Oyo Pi R 6 is an alkyl radical
- n and is 1 or 2 Can be produced or formulated in the same manner as described above, and can be used as a GPR40 receptor function regulator, a preventive / therapeutic agent for diabetes and the like
- MS mass spectrum
- Electron impact ionization method Electron impact ionization method (Electron Spray Ionization: ESI), Or Atmospheric Pressure Chemical Ionization (APCI). Unless otherwise specified, ESI was used.
- Solvent Solution A; water containing 0.1% trifluoroacetic acid,
- the melting point is, for example, a trace melting point analyzer (Janaco, MP-500D or Buchi, B-545) or DSC (differential scanning calorimetry). , EX STAR 600 000) and the like.
- the melting point may fluctuate depending on the measurement equipment, measurement conditions, and the like.
- the crystal in this specification may be a crystal exhibiting a value different from the melting point described in this specification as long as it is within a normal error range.
- the reaction mixture was poured into an aqueous solution of dihydrogen phosphate and sodium phosphate, and extracted with ethyl acetate.
- the ethyl acetate layer was dried over anhydrous magnesium sulfate, concentrated, and the residue was purified by silica gel column chromatography. Developing with ethyl acetate-hexane (Dalgent from 1: 9 to 2: 1 by volume) gave a yellow oil. This yellow oil was dissolved in tetrahydrofuran (30 mL), and lithium aluminum hydride (120 mg) was added to water. It was added little by little under cooling.
- reaction solution was diluted with ethyl acetate, washed sequentially with an aqueous solution of citrate, water and an aqueous solution of sodium hydroxide, dried over magnesium sulfate and concentrated under reduced pressure.
- N-propyl-4- [4_ (trifluoromethyl) phenyl] -1,3-thiazole-2-amine 700 mg, 2.44 mmol
- N, N-dimethylformamide 5 mL
- sodium hydride 100 mg, oily, 2.5 mmol
- Ethyl acid 700 rag, 2.0 ramol
- the organic layer was concentrated and the residue was purified by preparative HPLC.
- the obtained fraction was concentrated, neutralized with a 10% aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate.
- the ethyl acetate layer was filtered through a Presep dehydration tube (Wako Pure Chemical Industries, Ltd.) and concentrated to obtain the title compound as a yellow oil.
- the reaction mixture was poured into water and extracted with ethyl acetate.
- the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated.
- the residue was purified by silica gel column chromatography.
- the residue was developed with ethyl acetate-hexane (gradient from 1:19 to 1: 2 (volume ratio)) to give the title compound (340 mg, yield 68%) as a yellow oil.
- the title compound (262 mg, 75% yield) was obtained as colorless prisms (recrystallized from acetone-heptane) by developing with ethyl acetate-hexane (gradient from 1: 4 to 4: 1 (volume ratio)). .
- N- (3-Methynolebutyl) -4- [4- (trifluoromethyl) phenyl] -1,3-thiazol-2-amine 500 mg, 1.59 mmol
- N, N-dimethylformamide (10 mL ) Add 60% sodium hydride (63.6 mg, 1.59 mmol) to the solution, stir for 30 minutes, and add methyl 3- (4- ⁇ [4- (chloromethyl) benzyl] oxy ⁇ phenyl) propanoate (462 mg 1.45 mmol) was added. After the obtained mixture was stirred at room temperature for 13 hours, water was added to the reaction solution, and the mixture was extracted with ethyl acetate.
- Triphenyl ((4-phenyl-1,3) synthesized according to the method described in Liebigs Annaleri der Chemie, Vol. [Thiazole_2_yl) methyl] phosphonium bromide (1.0 g, 1.94 mraol) in benzene (20 mL) suspension was mixed with potassium t-butoxide (239 mg,
- Tetrahydrofuran (20 mL), methanol (10 mL) and 10% palladium on carbon (200 mg) were added to the oil, and the mixture was stirred under a hydrogen atmosphere at room temperature for 2 days.
- the catalyst was removed by filtration, and the obtained filtrate was concentrated to give a colorless oil.
- a 1.0 M solution of hydrogenated diisobutylaluminum toluene was added to a tetrahydrofuran (10 mL) solution of the oil.
- the solution (10 mL, 10 mraol) was added dropwise under ice cooling. After the reaction solution was stirred at room temperature for 2 hours, sodium sulfate decahydrate was added, and the mixture was further stirred at room temperature for 1 hour.
- the reaction mixture was poured into an aqueous solution of dihydrogen phosphate and 1-strength water, and extracted with ethyl acetate.
- the ethyl acetate layer was concentrated, and the residue was purified by basic silica gel column chromatography to obtain a yellow oil.
- a mixture of this yellow oil, 2N aqueous sodium hydroxide solution (2 mL) and ethanol (5 mL) was stirred at room temperature for 1 hour.
- the reaction mixture was poured into an aqueous solution of dihydrogen phosphate and 1 force of lithium, and extracted with ethyl acetate.
- Ethyl acetate layer in Presep Dehydration tube (Wako Pure Chemical Industries, Ltd.)
- Example 7 3- ⁇ 4-[(4- ⁇ [[2- (4-methylphenyl) ethyl] (4-phenyl-1,3_thiazol-2-yl) amino] methyl ⁇ benzyl) oxy] phen Nil ⁇ propanoic acid
- the title compound was synthesized in the same manner as in Example 4 from N- [2- (4-methylphenyl) ethyl] thiourea in a yield of 44%. Yellow oil.
- Example 1 23- ⁇ 4-[(4- ⁇ [(4-phenyl-1,3-thiazol-2-yl) (2-pyridine-2-ylethyl) amino] methyl ⁇ benzyl) oxy] fuel ⁇ Propanoic acid.
- Example 13 33- ⁇ 2-Fluoro-4-[(4- ⁇ [(4-phenyl-1,3-thiazol-2-inole) (2-pyridine-2-ylethyl) amino] methyl ⁇ benzyl) Oxy] pheninole ⁇ propanoic acid
- 3- ⁇ 2-fluoro-4-[(4 _ ⁇ [(4-phenyl-1,3-thiazol-2-yl) (2-pyridine-2-ylethyl) amino]]
- the title compound was synthesized in a 70% yield by basic hydrolysis of methyl ⁇ benzyl) oxy] phenyl ⁇ propanoate. Pale yellow crystals.
- Example 4 In the same manner as in Example 4, the title compound was synthesized from N- (3-phenylpropyl) thiourea and 2-bromo-1-pyridine-2-ylethanone in a yield of 27%. Brown solid.
- the ethyl acetate layer was dried using Presep Dehydration tube (manufactured by Wako Pure Chemical Industries, Ltd.), concentrated, and the residue was purified by silica gel column chromatography. Development with ethyl acetate-hexane (gradient from 1:19 to 1: 1 by volume) gave a yellow oil. This oil was dissolved in methanol (5 mL), 2N aqueous sodium hydroxide solution (2 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water, neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. After drying using a Presep Dehydration tube (manufactured by Wako Pure Chemical Industries, Ltd.), the filtrate was concentrated to obtain the title compound (105.rag, yield 41%) as ⁇ -color crystals.
- Example 15 In the same manner as in Example 15, the title compound was synthesized from 4-isobutyl-N- (2-phenylethyl) -1,3-thiazolyl-2-amine in a yield of 45%. Colorless crystals.
- Example 17 3- ⁇ 4-[(4- ⁇ [(3-phenylpropyl) (4-phenyl-1,3-thiazol-2-yl) amino] methyl ⁇ benzyl) oxy] phenyl ⁇ propane acid
- the title compound was synthesized from 4-phenyl-N- (3-phenylpropyl) 1,3-thiazol-2-amine in a yield of 41%. Pale yellow crystals.
- the ethyl acetate layer was dried using Presep Dehydration tube (manufactured by Wako Pure Chemical Industries, Ltd.), concentrated, and the residue was purified by silica gel column chromatography.
- the title compound (380 mg) was obtained as a yellow oil by developing with ethyl acetate-hexane (gradient from 1:19 to 1: 1 by volume).
- Example 19 9 3_ ⁇ 4-[(4- ⁇ [(2-phenylethyl) (4-propyl-1,3_thiazol-2-yl) amino] methyl ⁇ benzyl) oxy] phenyl ⁇ propanoic acid
- Feel ⁇ The title compound was synthesized in 84% yield by basic hydrolysis of methyl propanoate. Yellow oil.
- the ethyl acetate layer was dried using a Presep Dehydration tube (manufactured by Wako Pure Chemical Industries, Ltd.), concentrated, and the residue was purified by silica gel chromatography. Developing with ethyl acetate-hexane (gradient from 1:19 to 1: 1 by volume) yielded a yellow oil. This oil was dissolved in ethanol (5 mL), 2N aqueous sodium hydroxide solution (2 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water, neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. It was dried using Presep Dehydration tube (manufactured by Wako Pure Chemical Industries, Ltd.) and concentrated to give the title compound (206 mg, yield 71%) as a yellow oil.
- Presep Dehydration tube manufactured by Wako Pure Chemical Industries, Ltd.
- Example 2 7 3- ⁇ 2-Fluoro-4-[(4- ⁇ [[2- (4-fluorophenyl) ethyl] (4-isobutyl-1,3-thiazol-2-inole) amino] methyl ⁇ Benzyl) oxy] phenyl ⁇ propanoic acid
- the title compound was synthesized from N- [2- (4-fluoropheninole) ethyl] -4-isoptyl-1,3-thiazole-2-amine in a yield of 33%. Yellow oil.
- MS ra / z 565 (M + H).
- Example 18 In the same manner as in Example 18, the title compound was synthesized from 4-isopropyl-N- (2-phenyl earth tyl) -1,3-thiazol-2-amine in a yield of 68%. Yellow oil.
- the organic layer was concentrated under reduced pressure using a GeneVac centrifugal concentrator.
- the obtained product was dissolved in methanol (2 mL), 1N aqueous sodium hydroxide solution (0.32 mL, 0.32 mL) was added, and the mixture was stirred at room temperature for 18 hours.
- the reaction mixture was acidified with 1N hydrochloric acid, and extracted with dichloromethane (2 mL).
- the organic layer was concentrated under reduced pressure using a GeneVac centrifugal concentrator.
- the residue was purified by preparative HPLC (gradient cycle B) to give the title compound (4.6 mg, yield 5%). .
- the crystallized product was collected by filtration, and the obtained crude crystals were washed with water and hexane.
- the crystals were recrystallized from diisopropyl ether-hexane to give the title compound (128 mg, yield 78%) as a white powder.
- Example 36 3- [2-Fluoro-4-[[4-[[((2-f; c-nyletyl) (4-fuunyl-1,3-thiazol-2-yl) amino] methyl] benzyl] benzyl ] Phenyl] butanoic acid Using a method similar to that in Example 32, 3- [2-fluoro-4-[[4-[[(2-phenylethyl) (4-phenyl-1,3-thiazol-2-yl) ) Amino] methyl] benzyl] oxy] fuel] ethyl propanoate to give the title compound (39% yield) as colorless crystals.
- the reaction solution was diluted with ethyl acetate, washed with an aqueous solution of citric acid, water and saturated saline in that order, dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography, and crystallized from hexane to Jefferies chill ether one, the title compound (2 71 rag, 94% yield) was obtained as colorless prism crystals.
- N- (2-phenylethyl) -4- [4- (trifluoromethyl) phenyl] -1,3-thiazol-2-amine 500 mg, 1.43 mmol
- N, N-dimethylform Sodium hydride 50 mg, oily, 1.3 mmol
- 3- (4- ⁇ [4- (chloromethyl) benzyl] (Ethoxy) -2-fluorophenyl) propanoate 350 mg, 1.0 mmol
- the reaction mixture was poured into 1N hydrochloric acid and extracted with ethyl acetate.
- the organic layer was concentrated, and the residue was purified by silica gel column chromatography.
- the title compound was obtained as a yellow oil by developing with ethyl acetate / hexane (gradient from 1:19 to 3: 2 (volume ratio)).
- Example 43 The yellow oil obtained in 3 was dissolved in a mixed solvent of ethanol (5 mL) and tetrahydrofuran (5 mL), 2N aqueous sodium hydroxide solution ( 2 mL) was added, and the mixture was stirred at room temperature for 2 hours. . The reaction mixture was diluted with water, neutralized with 1N hydrochloric acid, and the precipitated solid was collected by filtration, washed with water, and dried to give the title compound (300 mg, 47% yield, 2 steps) as colorless Obtained as crystals.
- the reaction mixture was poured into 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by silica gel column chromatography. Development with ethyl acetate-hexane (gradient from 1:19 to 3: 2 (volume ratio)) yielded a yellow oil.
- the oil was dissolved in a mixed solvent of ethanol (5 mL) and tetrahydrofuran (5 mL), 2N aqueous sodium hydroxide solution (2 mL) was added, and the mixture was stirred at room temperature for 2 hours.
- the reaction mixture was poured into 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated to give the title compound (264 mg, 44% yield, 3 steps) as a pale green oil.
- N- [2_ (4-fluorophenyl) ethyl]-4- [4- (trifluoromethyl) phenyl] -1,3_thiazole-2-amine 500 mg, 1.36 mmol
- N Sodium hydride 40 mg, oily, 1.0 ramol
- (Chloromethyl) benzyl] oxy ⁇ _2-fluorophenyl) ethyl propane 350 mg, 1.0 mmol
- the reaction mixture was poured into 1N hydrochloric acid and extracted with ethyl acetate.
- the organic layer was concentrated, and the residue was purified by silica gel column chromatography. Hexane acetate Echiru to give a yellow oil and developed with (1:: 1 9 1 1 (by volume) gradient up).
- the oil was dissolved in a mixed solvent of ethanol (5 mL) and tetrahydrofuran (5 mL), 2N aqueous sodium hydroxide solution (2 mL) was added, and the mixture was stirred at room temperature for 2 hours.
- the reaction mixture was poured into 1N hydrochloric acid and extracted with ethyl acetate. After concentration of the organic layer, the residue was purified by preparative HPLC.
- the obtained fraction was concentrated, neutralized with a 10% aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate.
- the ethyl acetate layer was filtered through a Presep dehydration tube (Wako Pure Chemical Industries, Ltd.) and concentrated to give the title compound (139 mg, 21% yield, 2 steps) as a yellow oil.
- the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography. It was developed with ethyl acetate-hexane (gradient from 1:19 to 1: 2 (volume ratio)) to give a yellow oil. To a mixture of the oil, ethanol (5 raL) and tetrahydrofuran (5 mL) was added a 2N aqueous sodium hydroxide solution (2 mL), and the mixture was stirred at room temperature for 14 hours.
- the reaction mixture was diluted with water, neutralized with a 10% aqueous solution of citric acid, and extracted with ethyl acetate. After concentrating the organic layer, the residue was purified by silica gel column chromatography. The title compound (267 mg, yield 24%) was obtained as a yellow oil by developing with ethyl acetate-hexane (Dalgent from 1: 4 to 4: 1 (volume ratio)).
- Example 5 3_ ⁇ 2-Fluoro-4-[(4- ⁇ 1-[(4-phenyl-1,3-thiazol-2-ynole) sulfonyl] butyl ⁇ benzyl) oxy] phenyl ⁇ ethyl propanoate
- EC 5 The values were determined using a CHO cell line that stably expressed human-derived GPR40. Unless otherwise stated, this CHO cell line was cultured using a Hi-MEM medium (Invitrogen) containing 10% fetal calf serum (Invitrogen). On the day before Atsushi, cells cultured to near confluence were rinsed with PBS (In V itrogen), and then detached with 0.05% Tripsin 'EDTA solution (In V itrogen). And collected by centrifugation.
- Hi-MEM medium Invitrogen
- PBS In V itrogen
- Tripsin 'EDTA solution In V itrogen
- the number of the resulting cells was measured, diluted to contain media l mL per 3 x 1 0 5 cells, B lackwelled 9 6- wellplate (coster ) one by 1 0 0 mu L per well min After the injection, the cells were cultured in a CO 2 incubator. Various test compounds were added to the CHO cells thus prepared, and the fluctuation of the intracellular calcium concentration at this time was measured using FLIPR (Molecular Device). In order to measure the change in intracellular calcium concentration by FLIPR, the following pretreatment was performed.
- an assay buffer was prepared for adding the fluorescent dye F1uo3-AM (DOJIN) to the cells or for washing the cells immediately before performing the FLIPR assay.
- F1uo3-AM fluorescent dye F1uo3-AM
- F 1 uo 3 -AM 50 ⁇ g was dissolved in dimethyl sulfoxide (Wako, 21 ⁇ L), and an equal volume of 20% pullonic acid (Molecular Probe) was added. After adding s) and mixing, the mixture was added to Atsushi buffer (10.6 mL) to which fetal calf serum (105 / xL) was added to prepare a fluorescent dye solution. Before Atsushi B 1 ackwelled 96 before S-excluding the medium of CHO cells re-wound to wellpate, immediately dispensing 100 / L per well of the fluorescent dye solution, 1 hour in CO 2 incubator After culturing, the cells were allowed to incorporate the fluorescent dye.
- test compound was diluted with dimethyl sulfoxide before storage, dispensed in 2 Z 1 portions into 96-we11 latex (sample plate) made of polypropylene, and stored frozen at 120 ° C.
- sample plate 96-we11 latex
- CHAPS 0.015% CHAPS
- the compound (I) of the present invention, a salt thereof, and a prodrug thereof have an excellent GPR40 receptor function regulating action, and can be used as an agent for preventing or treating diabetes and the like.
- the present application is based on Japanese Patent Application No. 2003-435509, filed in Japan, the contents of which are incorporated in full herein.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005516723A JP4855777B2 (ja) | 2003-12-26 | 2004-12-24 | フェニルプロパン酸誘導体 |
EP04808099A EP1698624B1 (en) | 2003-12-26 | 2004-12-24 | Phenylpropanoic acid derivatives |
US10/584,730 US7585880B2 (en) | 2003-12-26 | 2004-12-24 | Phenylpropanoic acid derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003435089 | 2003-12-26 | ||
JP2003-435089 | 2003-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005063725A1 true WO2005063725A1 (ja) | 2005-07-14 |
Family
ID=34736589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/019749 WO2005063725A1 (ja) | 2003-12-26 | 2004-12-24 | フェニルプロパン酸誘導体 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7585880B2 (ja) |
EP (1) | EP1698624B1 (ja) |
JP (1) | JP4855777B2 (ja) |
WO (1) | WO2005063725A1 (ja) |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525516A (ja) * | 2004-02-27 | 2007-09-06 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
JPWO2005095338A1 (ja) * | 2004-03-30 | 2008-02-21 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
WO2008066097A1 (en) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
WO2009054423A1 (ja) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | オキサジアゾリジンジオン化合物 |
US7572934B2 (en) | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
US7687526B2 (en) | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
WO2010035806A1 (ja) | 2008-09-25 | 2010-04-01 | 武田薬品工業株式会社 | 固形医薬組成物 |
WO2010050445A1 (ja) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
WO2010076884A1 (ja) | 2008-12-29 | 2010-07-08 | 武田薬品工業株式会社 | 新規縮合環化合物およびその用途 |
WO2010080864A1 (en) | 2009-01-12 | 2010-07-15 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
WO2010123016A1 (ja) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | カルボン酸化合物 |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
WO2011013639A1 (ja) | 2009-07-28 | 2011-02-03 | 武田薬品工業株式会社 | 錠剤 |
US7932289B2 (en) | 2004-07-27 | 2011-04-26 | Takeda Pharmaceutical Company Limited | Remedy for diabetes |
US7968552B2 (en) | 2006-04-24 | 2011-06-28 | Astellas Pharma Inc. | Oxadiazolidinedione compound |
US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
WO2011136385A1 (en) | 2010-04-27 | 2011-11-03 | Takeda Pharmaceutical Company Limited | Bicyclic compound derivatives and their use as acc inhibitors. |
WO2011158880A1 (ja) | 2010-06-16 | 2011-12-22 | 武田薬品工業株式会社 | アミド化合物の結晶 |
WO2012036293A1 (ja) | 2010-09-17 | 2012-03-22 | 武田薬品工業株式会社 | 糖尿病治療剤 |
US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
WO2012074126A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
WO2012111849A1 (en) | 2011-02-17 | 2012-08-23 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
US8450522B2 (en) | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
WO2013105676A1 (en) | 2012-01-12 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
WO2013122260A1 (en) | 2012-02-15 | 2013-08-22 | Takeda Pharmaceutical Company Limited | Tablet |
WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013122028A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013125732A1 (en) | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168760A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168759A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013183784A1 (en) | 2012-06-05 | 2013-12-12 | Takeda Pharmaceutical Company Limited | Solid preparation |
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
WO2015005489A1 (en) | 2013-07-09 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015020184A1 (ja) | 2013-08-09 | 2015-02-12 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2015052910A1 (en) | 2013-10-07 | 2015-04-16 | Takeda Pharmaceutical Company Limited | Antagonists of somatostatin receptor subtype 5 (sstr5) |
WO2015122188A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015122187A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
WO2018182050A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders |
WO2018182051A1 (en) | 2017-03-30 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Ip6k inhibitors |
WO2018181847A1 (ja) | 2017-03-31 | 2018-10-04 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2018181864A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Gip receptor activating peptide |
WO2020045326A1 (ja) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
WO2020067575A1 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2020067557A2 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2021193984A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
WO2021193983A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
WO2022241287A2 (en) | 2021-05-13 | 2022-11-17 | Carmot Therapeutics, Inc. | Modulators of g-protein coupled receptors |
US11535660B1 (en) | 2018-03-23 | 2022-12-27 | Cannot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
WO2024138048A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
SI2248812T1 (sl) | 2006-06-27 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Kondenzirane ciklične spojine kot modulatorji GPR40 receptorja |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
KR20090113382A (ko) * | 2007-02-22 | 2009-10-30 | 아이알엠 엘엘씨 | G 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체 |
WO2011151436A2 (en) * | 2010-06-04 | 2011-12-08 | Euroscreen S.A. | Novel compounds, method for use them and pharmaceutical composition containing them |
WO2011161690A1 (en) * | 2010-06-23 | 2011-12-29 | Symed Labs Limited | Processes for the preparation of (+)-n,n-dimethyl-2-[1-(naphthalenyloxy) ethyl] benzene methanamine and intermediates thereof |
JP6054368B2 (ja) | 2011-04-08 | 2016-12-27 | カルダン セラピューティクス リミテッドCaldan Therapeutics Limited | 代謝性疾患治療用o−フルオロ置換化合物またはその塩 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
EP3177287B1 (en) | 2014-08-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
CN107556252A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院上海药物研究所 | 一种含吡嗪环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 |
EP3709995A4 (en) | 2017-11-16 | 2021-04-14 | Merck Sharp & Dohme Corp. | BICYCLIC ANTIDIABETIC COMPOUNDS |
CN108003074B (zh) * | 2017-12-21 | 2019-07-05 | 四川大学华西医院 | 联苯羧酸类化合物及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07505647A (ja) * | 1992-04-10 | 1995-06-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 複素環化合物および2型糖尿病の治療におけるそれらの使用 |
WO2002053547A1 (fr) * | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Derives d'acide alcanoique, procede de production et utilisation correspondants |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
WO1999011255A1 (fr) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Regulateurs du recepteur active par les agents de proliferation des peroxysomes |
PL351470A1 (en) | 1999-04-28 | 2003-04-22 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
HUP0204574A3 (en) | 2000-01-28 | 2003-08-28 | Novo Nordisk As | Propionic acid derivatives and their use in the treatment of diabetes and obesity, pharmaceutical compositions containing them and their preparation |
JP4148681B2 (ja) * | 2000-12-28 | 2008-09-10 | 武田薬品工業株式会社 | アルカン酸誘導体、その製造法および用途 |
WO2002083616A1 (fr) | 2001-04-10 | 2002-10-24 | Sankyo Company, Limited | DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE |
GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
EP1535915A4 (en) | 2002-09-06 | 2005-10-05 | Takeda Pharmaceutical | FURANE OR THIOPHENE DERIVATIVE AND PHARMACEUTICAL USES THEREOF |
JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
-
2004
- 2004-12-24 US US10/584,730 patent/US7585880B2/en not_active Expired - Fee Related
- 2004-12-24 EP EP04808099A patent/EP1698624B1/en not_active Not-in-force
- 2004-12-24 WO PCT/JP2004/019749 patent/WO2005063725A1/ja not_active Application Discontinuation
- 2004-12-24 JP JP2005516723A patent/JP4855777B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07505647A (ja) * | 1992-04-10 | 1995-06-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 複素環化合物および2型糖尿病の治療におけるそれらの使用 |
WO2002053547A1 (fr) * | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Derives d'acide alcanoique, procede de production et utilisation correspondants |
EP1357115A1 (en) | 2000-12-28 | 2003-10-29 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
Non-Patent Citations (1)
Title |
---|
MITSUNOBU REACTION, (SYNTHESIS, 1981, pages 1 - 27 |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7649110B2 (en) | 2004-02-27 | 2010-01-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
JP2007525516A (ja) * | 2004-02-27 | 2007-09-06 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
US7816367B2 (en) | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
JPWO2005095338A1 (ja) * | 2004-03-30 | 2008-02-21 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
US7932289B2 (en) | 2004-07-27 | 2011-04-26 | Takeda Pharmaceutical Company Limited | Remedy for diabetes |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
US7968552B2 (en) | 2006-04-24 | 2011-06-28 | Astellas Pharma Inc. | Oxadiazolidinedione compound |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
US8003648B2 (en) | 2006-09-07 | 2011-08-23 | Amgen Inc. | Heterocyclic GPR40 modulators |
US7687526B2 (en) | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
WO2008066097A1 (en) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
JP2010524932A (ja) * | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質 |
US7572934B2 (en) | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
WO2009054423A1 (ja) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | オキサジアゾリジンジオン化合物 |
US8450522B2 (en) | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
WO2010035806A1 (ja) | 2008-09-25 | 2010-04-01 | 武田薬品工業株式会社 | 固形医薬組成物 |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
WO2010050445A1 (ja) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
WO2010076884A1 (ja) | 2008-12-29 | 2010-07-08 | 武田薬品工業株式会社 | 新規縮合環化合物およびその用途 |
WO2010080864A1 (en) | 2009-01-12 | 2010-07-15 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
WO2010123016A1 (ja) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | カルボン酸化合物 |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
WO2011013639A1 (ja) | 2009-07-28 | 2011-02-03 | 武田薬品工業株式会社 | 錠剤 |
WO2011136385A1 (en) | 2010-04-27 | 2011-11-03 | Takeda Pharmaceutical Company Limited | Bicyclic compound derivatives and their use as acc inhibitors. |
WO2011158880A1 (ja) | 2010-06-16 | 2011-12-22 | 武田薬品工業株式会社 | アミド化合物の結晶 |
WO2012036293A1 (ja) | 2010-09-17 | 2012-03-22 | 武田薬品工業株式会社 | 糖尿病治療剤 |
WO2012074126A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
WO2012111849A1 (en) | 2011-02-17 | 2012-08-23 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
WO2013105676A1 (en) | 2012-01-12 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
WO2013122028A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013122260A1 (en) | 2012-02-15 | 2013-08-22 | Takeda Pharmaceutical Company Limited | Tablet |
WO2013125732A1 (en) | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168760A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013168759A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2013183784A1 (en) | 2012-06-05 | 2013-12-12 | Takeda Pharmaceutical Company Limited | Solid preparation |
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
WO2015005489A1 (en) | 2013-07-09 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015020184A1 (ja) | 2013-08-09 | 2015-02-12 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2015052910A1 (en) | 2013-10-07 | 2015-04-16 | Takeda Pharmaceutical Company Limited | Antagonists of somatostatin receptor subtype 5 (sstr5) |
WO2015122188A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015122187A1 (en) | 2014-02-13 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
WO2018182051A1 (en) | 2017-03-30 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Ip6k inhibitors |
WO2018182050A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders |
WO2018181864A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Gip receptor activating peptide |
WO2018181847A1 (ja) | 2017-03-31 | 2018-10-04 | 武田薬品工業株式会社 | 芳香環化合物 |
US11535660B1 (en) | 2018-03-23 | 2022-12-27 | Cannot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
WO2020045326A1 (ja) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
WO2020067557A2 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2020067575A1 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2021193983A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
WO2021193984A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
WO2022241287A2 (en) | 2021-05-13 | 2022-11-17 | Carmot Therapeutics, Inc. | Modulators of g-protein coupled receptors |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
WO2024138048A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Also Published As
Publication number | Publication date |
---|---|
US7585880B2 (en) | 2009-09-08 |
EP1698624A1 (en) | 2006-09-06 |
US20070155808A1 (en) | 2007-07-05 |
JPWO2005063725A1 (ja) | 2007-07-19 |
EP1698624B1 (en) | 2012-06-27 |
JP4855777B2 (ja) | 2012-01-18 |
EP1698624A4 (en) | 2008-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005063725A1 (ja) | フェニルプロパン酸誘導体 | |
CA2527691C (en) | Condensed ring compound | |
US7456218B2 (en) | 3-(4-benzyloxyphenyl) propanoic acid derivatives | |
JP4875978B2 (ja) | アミノフェニルプロパン酸誘導体 | |
EP1731505B1 (en) | Alkoxyphenylpropanoic acid derivatives | |
JP4917634B2 (ja) | 縮合環化合物 | |
WO2007013689A1 (ja) | シクロプロパンカルボン酸化合物 | |
JP4805552B2 (ja) | 縮合環化合物 | |
JP4074616B2 (ja) | 3−(4−ベンジルオキシフェニル)プロパン酸誘導体 | |
JPWO2009128481A1 (ja) | 含窒素5員複素環化合物 | |
KR20070018827A (ko) | 3-(4-벤질옥시페닐)프로판산 유도체 | |
MXPA06006597A (en) | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516723 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004808099 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10584730 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004808099 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10584730 Country of ref document: US |